<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>As filed with the U.S. Securities and Exchange Commission on November 15, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>180 Life Sciences Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><B>2834</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><B>90-1890354</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>(State or other jurisdiction of</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(Primary Standard Industrial</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(I.R.S. Employer</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>incorporation or organization)</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Classification Code Number)</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Identification Number)</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3000 El Camino Real, Bldg. 4, Suite 200<BR>
Palo Alto, CA&nbsp;94306<BR>
(650)&nbsp;507-0669</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mr. Blair Jordan<BR>
Chief Executive Officer<BR>
180 Life Sciences Corp.<BR>
3000 El Camino Real, Bldg. 4, Suite 200<BR>
Palo Alto, CA&nbsp;94306<BR>
(650)&nbsp;507-0669</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David M. Loev, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>John S. Gillies, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Loev Law Firm, PC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6300 West Loop South, Suite 280</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bellaire, Texas 77401</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (713)&nbsp;524-4110</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Approximate date of commencement
of proposed sale to the public:</B>&nbsp;From time to time after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule 462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule 462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of &ldquo;<U>large accelerated filer,</U>&rdquo; &ldquo;<U>accelerated filer,</U>&rdquo; &ldquo;<U>smaller
reporting company,</U>&rdquo; and &ldquo;<U>emerging growth company</U>&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 24%">Large&nbsp;accelerated&nbsp;filer</TD>
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 28%">Accelerated filer</TD>
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD>Smaller&nbsp;reporting&nbsp;company</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Emerging&nbsp;growth&nbsp;company</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><B><I>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the
Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section&nbsp;8(a), may determine.</I></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information contained
in this prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>SUBJECT TO COMPLETION,
DATED NOVEMBER 15, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,900,138 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates solely
to the offer and sale from time to time of up to an aggregate of 1,900,138 shares of our common stock, par value $0.0001 per share, of
180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company,</U>&rdquo; &ldquo;<U>we,</U>&rdquo; &ldquo;<U>our</U>&rdquo; or
&ldquo;<U>us</U>&rdquo;), by the selling stockholder identified in this prospectus (the &ldquo;<U>Selling Stockholder</U>&rdquo;). The
shares of common stock being registered for resale hereunder consist of: 1,900,138 shares of common stock issuable upon the exercise of
the October 2024 Warrants (as defined herein), acquired by the Selling Stockholder, pursuant to an Inducement Agreement (as defined herein)
entered into between us and the Selling Stockholder (the &ldquo;<U>Warrants,</U>&rdquo; and all of the shares of common stock issuable
upon exercise of the Warrants, the &ldquo;<U>Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Warrants are exercisable
at an exercise price of $1.50. We are not selling any common stock under this prospectus and will not receive any of the proceeds from
the sale of the Shares by the Selling Stockholder. However, if all of the Warrants that are covered by this prospectus are exercised for
cash, we may receive proceeds of up to approximately $2,850,207. We intend to use those proceeds, if any, for operationalizing and developing
our recently acquired Technology Gaming Platform, and general corporate and legal expenses. We will bear all other costs, expenses and
fees in connection with the registration of the Shares. The Selling Stockholder will bear all commissions and discounts, if any, attributable
to the sales of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder may
offer such Shares from time to time as it may determine through public or private transactions or through other means described in the
section entitled &ldquo;<I><U>Plan of Distribution</U></I>&rdquo; beginning on page 18 of this prospectus, at prevailing market prices,
at prices related to prevailing market prices or at privately negotiated prices. This prospectus does not necessarily mean that the Selling
Stockholder will offer or sell the Shares. We cannot predict when or in what amounts the Selling Stockholder may sell any of the Shares
offered by this prospectus. Any Shares subject to resale hereunder will have been issued by us and acquired by the Selling Stockholder
prior to any resale of such Shares pursuant to this prospectus. Because all of the Shares offered under this prospectus are being offered
by the Selling Stockholder, we cannot currently determine the price or prices at which the Shares may be sold under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the Nasdaq Capital Market (&ldquo;<U>Nasdaq</U>&rdquo;)&nbsp;under the symbol &ldquo;<U>ATNF</U>&rdquo;. On November 14, 2024, the
last reported sale price for our common stock as reported on Nasdaq was $2.68 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>INVESTING IN OUR SECURITIES
INVOLVES SUBSTANTIAL RISKS.&nbsp;SEE THE SECTION TITLED &ldquo;<U>RISK FACTORS</U>&rdquo; BEGINNING ON PAGE 7 OF THIS PROSPECTUS TO READ
ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING OUR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NEITHER THE SECURITIES
AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY
OR ACCURACY OF THIS PROSPECTUS.&nbsp;ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left"><A HREF="#a_001">About This Prospectus</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">iii</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_002">Prospectus Summary</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_003">Risk Factors</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_004">Incorporation by Reference</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_005">Cautionary Note Regarding Forward-Looking Statements</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_006">Use of Proceeds</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_007">Dividend Policy</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_008">Beneficial Ownership of Securities</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_009">Selling Stockholder</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_010">Plan of Distribution</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_011">Description of Capital Stock</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_012">Legal Matters</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_013">Experts</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_014">Where You Can Find More Information</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our logo and some of our trademarks
and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property
of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the &reg;,
&trade; and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will
not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective
owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market data and certain
other statistical information used throughout this prospectus are based on independent industry publications, reports by market research
firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey
data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness
of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications
and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are
not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as
they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various
factors, including those discussed under the section entitled &ldquo;<I><U>Risk Factors</U></I>&rdquo; of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included
herein, as well as the data of competitors as they relate to 180 Life Sciences Corp., is also based on our good faith estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context requires
otherwise, references to the &ldquo;<U>Company,</U>&rdquo; &ldquo;<U>we,</U>&rdquo; &ldquo;<U>us,</U>&rdquo; &ldquo;<U>our,</U>&rdquo;
&ldquo;<U>180 Life</U>&rdquo;, &ldquo;<U>180LS</U>&rdquo; and &ldquo;<U>180 Life Sciences Corp.</U>&rdquo; refer specifically to 180 Life
Sciences Corp. and its consolidated subsidiaries. References to &ldquo;<U>KBL</U>&rdquo; refer to the Company prior to the November 6,
2020 Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, unless the context
otherwise requires and for the purposes of this prospectus only:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>CAD</U>&rdquo; refers to Canadian dollars;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>Exchange Act</U>&rdquo; refers to the Securities
Exchange Act of 1934, as amended;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>&pound;</U>&rdquo; or &ldquo;<U>GBP</U>&rdquo; refers
to British pounds sterling;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>SEC</U>&rdquo; or the &ldquo;<U>Commission</U>&rdquo;
refers to the United States Securities and Exchange Commission; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>Securities Act</U>&rdquo; refers to the Securities
Act of 1933, as amended.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on December 19,
2022 at 12:01 a.m. Eastern Time, we affected a 1-for-20 reverse stock split of our then outstanding common stock, with any fractional
shares rounded up to the nearest whole share. Effective on February 28, 2024 at 12:01 a.m. Eastern Time, we affected a 1-for 19 reverse
stock split of our then outstanding common stock with any fractional shares rounded up to the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the reverse
splits, all outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common
stock were adjusted, as required by the terms of each security. The number of shares available to be awarded under the Company&rsquo;s
equity incentive plans were also appropriately adjusted. Following the reverse splits, the par value of the common stock remained unchanged
at $0.0001 par value per share. The reverse splits did not change the authorized number of shares of common stock or preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effects of the reverse
stock splits have been retroactively reflected throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_001"></A>About This Prospectus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form S-1 that we filed with the SEC. Under this registration statement, the Selling Stockholder may, from
time to time, sell the shares of common stock offered by it as described in this prospectus. We will not receive any proceeds from the
sale by such Selling Stockholder of the Shares offered by it as described in this prospectus. We will not receive any proceeds from the
sale of Shares pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor the Selling
Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this
prospectus or any applicable prospectus supplement or any free writing prospectus prepared by or on behalf of us or to which we have referred
you. Neither we nor the Selling Stockholder take responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. Neither we nor the Selling Stockholder will make an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any
date other than the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed since
that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also provide a prospectus
supplement or post-effective amendment to the registration statement to add information to, or update or change information contained
in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the
registration statement together with the additional information to which we refer you in the sections of this prospectus entitled &ldquo;<I><U>Incorporation
by Incorporation</U></I>&rdquo; and &ldquo;<I><U>Where You Can Find More Information.</U></I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_002"></A>Prospectus Summary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary highlights
selected information contained elsewhere in this prospectus and/or incorporated by reference herein, and does not contain all of the information
that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire
prospectus and the information incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a clinical
stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis
by employing innovative research, and, where appropriate, combination therapy. In September 2024, we completed the acquisition of certain
source code and intellectual property relating to an online blockchain casino, and moving forward, we plan to focus the majority of our
operations on the creation of the online blockchain casino, while still working to complete the development of certain prior therapeutics
for unmet medical needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Biotechnology Product Development</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have three product development
platforms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">fibrosis and anti-tumor necrosis factor (&ldquo;<U>TNF</U>&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">drugs which are derivatives of cannabidiol (&ldquo;<U>CBD</U>&rdquo;) or cannabigerol (&ldquo;<U>CBG</U>&rdquo;) analogues (&ldquo;<U>SCAs</U>&rdquo;); and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">alpha 7 nicotinic acetylcholine receptor (&ldquo;<U>&alpha;7nAChR</U>&rdquo;).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Due
to restrictions in the Company&rsquo;s resources, the Company has slowed down research and development activities significantly in the
SCA platform and the anti-TNF platform, and the Company has not made progress in the &alpha;7nAChR platform and has suspended further
research and development activity in this program in the meantime. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Company is currently evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to
maximize value for its stockholders. Potential strategic alternatives that may be explored or evaluated by the Company as part of this
process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sale of assets, licensing
or other strategic transactions involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Planned iGaming Casino
Operations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2024, we
entered into an Asset Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;)&nbsp;with Elray Resources, Inc. (&ldquo;<U>Elray</U>&rdquo;).
Pursuant to the Purchase Agreement, Elray agreed to sell us certain source code and intellectual property relating to an online blockchain
casino (the &ldquo;<U>Purchased Assets</U>&rdquo;)&nbsp;in consideration for 1,000,000 shares of newly designated Series B Convertible
Preferred Stock (the &ldquo;<U>Preferred Stock</U>&rdquo;, and the shares of common stock issuable upon conversion thereof, the &ldquo;<U>Conversion
Shares</U>&rdquo;)&nbsp;and warrants to purchase 3,000,000 shares of common stock of the Company (the &ldquo;<U>Purchase Warrants</U>&rdquo;
and the shares of common stock issuable upon exercise thereof, the &ldquo;<U>Purchase Warrant Shares</U>&rdquo;). The acquisition of the
Purchased Assets was completed on September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are planning to strategically
enter into the online gaming industry, utilizing the Purchased Assets, i.e., our newly acquired &ldquo;<U>back-end</U>&rdquo; gaming platform,
which incorporates blockchain technology and full cryptocurrency operability (the &ldquo;<U>Gaming Technology Platform</U>&rdquo;). The
Company plans to use this technology platform to establish a blockchain-based business aimed at the global iGaming market. Initially focusing
on B2C (business-to-consumer) online casinos, the Company also plans to expand into a B2B (business-to-business) model, offering a seamless
blockchain-enabled technology platform for gaming operators worldwide. In addition, management has identified certain global iGaming industry
characteristics and trends that they believe make potential acquisition opportunities attractive. Management believes that the combination
of the Gaming Technology Platform and the strength of a Nasdaq listing make the Company an attractive consolidation vehicle for the iGaming
industry, and plan to work to identify potential acquisitions (although no targets exist at present).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</div>
<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants and Related Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>August 2023 Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 9, 2023, the Company
entered into a Securities Purchase Agreement (the &ldquo;<U>August SPA</U>&rdquo;) with the Selling Stockholder, an accredited investor
(the &ldquo;<U>Purchaser</U>&rdquo;), in addition to certain purchasers, pursuant to which the Company agreed to sell an aggregate of
35,102 shares of common stock (the &ldquo;<U>August 2023 Shares</U>&rdquo;), pre-funded warrants to purchase up to an aggregate of 207,814
shares of common stock (&ldquo;<U>August 2023 Pre-Funded Warrants</U>&rdquo;), and common stock warrants to purchase up to an aggregate
of 242,915 shares of common stock (the &ldquo;<U>August 2023 Common Warrants</U>&rdquo;), at a combined purchase price of $12.35 per share
and warrant (the &ldquo;<U>August 2023 Offering</U>&rdquo;). Aggregate gross proceeds from the August 2023 Offering were $2,999,606. Net
proceeds to the Company from the offering, after deducting the placement agent fees and other offering expenses payable by the Company,
were approximately $2.7 million. The placement agent fees and offering expenses of approximately $300,000 were accounted for as a reduction
of additional paid in capital. The August 2023 Offering closed on August 14, 2023.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Amendment to August 2023 Offering </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 11, 2023, the Company
received a letter from Listing Qualifications Department of The Nasdaq Stock Market LLC (&ldquo;<U>Nasdaq</U>&rdquo;), stating that Nasdaq
had determined that the Company failed to comply with Nasdaq&rsquo;s shareholder approval requirements set forth in Listing Rule 5635(d),
which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the
pre-transaction shares outstanding at less than the Minimum Price. The letter from Nasdaq referred to the August 2023 Offering and requested
the Company to submit a plan of compliance no later than November 27, 2023. On November 9, 2023, the Company submitted a plan of compliance
to Nasdaq, and on November 14, 2023, Nasdaq provided a letter of extension to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the compliance
plan submitted to Nasdaq, on November 28, 2023, the Company entered into an amendment to the August 2023 Offering (&ldquo;<U>Amendment
to the August 2023 Offering</U>&rdquo;), whereby (i)&nbsp;the Purchaser agreed to pay an additional $830,769 in connection with the repricing
of the August 2023 Shares and August 2023 Pre-Funded Warrants (the &ldquo;<U>Repricing Amount</U>&rdquo;), (ii) the Company agreed to
issue to the Purchaser additional pre-funded warrants to purchase up to 257,205 shares of common stock, with an exercise price of $0.0019
per share (the &ldquo;<U>Additional Pre- Funded Warrants</U>&rdquo;), and warrants to purchase up to 477,058 shares of common stock, with
an exercise price of $3.23 per share (the &ldquo;<U>Additional Common Warrants</U>&rdquo;, and collectively with the Additional Pre-Funded
Warrants, the &ldquo;<U>Additional Warrants</U>&rdquo;), and (iii)&nbsp;the Company and the Purchaser agreed to enter into a warrant amendment
agreement (as described below). Net proceeds to the Company from the repricing, after deducting the placement agent fees and other offering
expenses payable by the Company, were approximately $0.8 million. The placement agent fees and offering expenses of approximately $60,000
were accounted for as a reduction of additional paid in capital. The Amendment to the August 2023 Offering closed on December 1, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Amendment
to the August 2023 Offering, the Company entered into a warrant amendment agreement to amend the following outstanding warrants held by
the Purchaser: (i)&nbsp;warrants to purchase up to 16,138 shares of common stock issued in July 2022; (ii) warrants to purchase up to
135,339 shares of common stock issued in December 2022; (iii) warrants to purchase up to 82,668 shares of common stock issued in April
2023; and (iv) warrants to purchase up to 242,915 shares of common stock issued in August 2023 (collectively, the &ldquo;<U>Existing Common
Warrants</U>&rdquo;). Pursuant to the warrant amendment agreement, the Existing Common Warrants were amended to have an exercise price
of $3.23 per share, and to expire on the fifth anniversary of the date that the stockholders of the Company approved the issuance of shares
of common stock upon exercise of such Existing Common Warrants, which stockholder approval date, which was February 16, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
</div>
<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Inducement Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 16, 2024, we entered into a warrant inducement agreement (the &ldquo;<U>Inducement Agreement</U>&rdquo;) with Armistice Capital
Master Fund Ltd. (the &ldquo;<U>Holder</U>&rdquo;) of 477,058 Additional Common Warrants and 473,011 of the Existing Common Warrants (collectively,
the &ldquo;<U>Exercised Warrants</U>&rdquo;), pursuant to which the Holder agreed to exercise for cash the Exercised Warrants to purchase
950,069 shares of common stock at an exercise price of $3.48 per share ($0.25 greater than the $3.23 per share exercise price of such
Exercised Warrants). On
October 16 and 17, 2024, the Exercised Warrants were exercised in full for cash by the Holder and the Company received $3,306,240 before
deducting financial advisory fees and other expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
consideration of the Holder&rsquo;s agreement to exercise the Exercised Warrants in accordance with the Inducement Agreement, the Company
agreed to issue new unregistered Warrants to Purchase Shares of Common Stock (the &ldquo;<U>October 2024 Warrants</U>&rdquo;) to purchase
a number of shares of common stock equal to 200% of the number of shares of common stock issued upon exercise of the Exercised Warrants,
i.e., warrants to purchase up to 1,900,138 shares of common stock (the &ldquo;<U>October 2024 Warrant Shares</U>&rdquo;). The October
2024 Warrants were immediately exercisable and have a term of exercise of five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company agreed in the Inducement Agreement to file a registration statement on Form S-1 to register the resale of the New Warrant Shares
upon exercise of the October 2024 Warrants (the &ldquo;<U>Resale Registration Statement</U>&rdquo;) by November 15, 2024, and to use commercially
reasonable efforts to have such Resale Registration Statement declared effective by the Commission within sixty (60) calendar days following
the date of filing with the Commission (or ninety (90) calendar days following the date of filing with the Commission in the event of
a &lsquo;full review&rsquo; by the Commission) and to keep the Resale Registration Statement effective at all times until no holder of
the October 2024 Warrants owns any October 2024 Warrants or October 2024 Warrant Shares. In the event that the Company fails to timely
deliver to the Holder the October 2024 Warrant Shares without restrictive legends, the Company has agreed to pay certain liquidated damages
to the Holder. The registration statement of which this prospectus forms a part is the required Resale Registration Statement, which was
timely filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company has used, and plans to continue to use, the net proceeds from these transactions&nbsp;to advance the commercialization of the
Purchased Assets recently acquired by the Company,&nbsp;and for working capital, and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
October 2024 Warrants have an exercise price of $1.50 per share. The exercise price and the number of shares of common stock issuable
upon exercise of each October 2024 Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances,
upon a fundamental transaction, a holder of October 2024 Warrants will be entitled to receive, upon exercise of the October 2024 Warrants,
the kind and amount of securities, cash or other property that such holder would have received had they exercised the October 2024 Warrants
immediately prior to the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company may not affect the exercise of October 2024 Warrants, and the applicable Holder will not be entitled to exercise any portion of
any such October 2024 Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock
beneficially owned by the holder of such October 2024 Warrant (together with its affiliates) to exceed 4.99% or 9.99%, as applicable,
of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of such October 2024 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company engaged A.G.P./Alliance Global Partners (&ldquo;<U>A.G.P.</U>&rdquo;) to provide exclusive financial services in connection with
the transactions summarized above and, pursuant to a Financial Advisory Agreement between the Company and A.G.P., paid A.G.P. a financial
advisory fee of $232,000, and an alternative transaction fee of $100,000. In addition, we reimbursed A.G.P. for its accountable legal
expenses in connection with the exercise of the Exercised Warrants and the issuance of the October 2024 Warrants of $65,000 and $10,000
of non-accountable expenses. In addition, we paid A.G.P. $29,923, half of the financial advisory fees due in connection with advisory
fees in 2023 and agreed to pay $29,923 for advisory fees in the future. As of October 31, 2024, a total of $436,923 related to the aforementioned
transaction has been paid to A.G.P in addition to the $29,923 of advisory fee, and there is a balance outstanding of $29,923 for the aforementioned
advisory fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
</div>
<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were originally formed
as KBL Merger Corp. IV, a blank check company organized under the laws of the State of Delaware on September 7, 2016, which consummated
its initial public offering on June 7, 2017. On November 6, 2020, we consummated a business combination and, in connection therewith,
changed our name to 180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, and our telephone number is (650)&nbsp;507-0669.&nbsp;We
maintain a website at www.180lifesciences.com. We have not incorporated by reference into this prospectus the information in, or that
can be accessed through, our website, and you should not consider it to be a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 17%"><B><I>Shares offered by the Selling Stockholder:</I></B></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 82%; text-align: justify">We are registering the resale by the Selling Stockholder named in this prospectus, or their permitted transferees, of an aggregate of up to an aggregate of 1,900,138 Shares by the Selling Stockholder identified in this prospectus. The Shares being registered for resale hereunder consist of the shares of common stock issuable upon exercise of the October 2024 Warrants.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B><I>Common stock outstanding prior to this offering:</I></B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>1,976,999 shares of common stock as of November 15, 2024.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B><I>Use of proceeds:</I></B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">The Selling Stockholder will receive the proceeds from the sale of the Shares offered hereby. We will not receive any proceeds from the sale of the Shares. However, if all of the Warrants that are covered by this prospectus are exercised for cash, we may receive proceeds of up to approximately $2,850,207.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Risk Factors:</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">The purchase of our securities involves a high degree of risk. See &ldquo;<I><U>Risk Factors</U></I>&rdquo; beginning on page 7 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Nasdaq Symbol:</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>Our common stock is listed on Nasdaq under the symbol &ldquo;<U>ATNF</U>&rdquo;.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of our
common stock outstanding is based on 1,900,138 shares outstanding as of November 15, 2024, and excludes, as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">22,956 shares of common stock issuable upon the exercise of
outstanding stock options;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">6,397 additional shares of our common stock reserved for future
issuance under our 2020 Omnibus Incentive Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">16,052 additional shares of our common stock reserved for
future issuance under our 2022 Omnibus Incentive Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">(a) 15,132 shares of common stock issuable upon the exercise
of outstanding public warrants exercisable at an exercise price of $4,370.00 per share, (b) 6,748 shares of common stock issuable upon
the exercise of certain outstanding private placement warrants at an exercise price of $1,900.00 per share, (d) 6,579 shares of common
stock issuable upon the exercise of certain outstanding private placement warrants at an exercise price of $2,850.00 per share, (e) 4,049
shares of common stock issuable upon exercise of certain outstanding warrants to purchase shares of common stock with an exercise price
of $3.23 per share, (f) 3,000,000 shares of common stock issuable upon the exercise of warrants to purchase 3,000,000 shares of common
stock with an exercise price of $1.68 per share, (g) 168 shares of common stock issuable upon exercise of warrants which expire on May
2, 2025, and (h) 1,900,138 shares of common stock issuable upon exercise of the October 2024 Warrants, with an exercise price of $1.50
per share; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">up to a maximum of 10,000,000 shares of common stock issuable
upon conversion of 1,000,000 shares of Series B Convertible Preferred Stock.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>
</div>
<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face risks and uncertainties
related to our business, many of which are beyond our control. In particular, risks associated with our business include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our need for additional financing, both near term and long
term, to support our operations, our ability to raise such financing as needed, the terms of such financing, if available, potential
significant dilution associated therewith, and covenants and restrictions we may need to comply with in connection with such funding.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to create or purchase a front end for our back
end blockchain casino intellectual property assets, commercialize our planned blockchain casino, obtain required licenses and customers,
and ultimately generate revenues through such operations.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The fact that we are currently an iGaming/clinical stage biotechnology
company that had no revenue for the three or nine months ended September 30, 2024, and for the years ended December 31, 2023 and 2022,
and may not generate significant revenue for the near term.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our dependence on the success of our future product candidates,
some of which may not receive regulatory approval or be successfully commercialized; problems in our manufacturing process for our new
products and/or our failure to comply with manufacturing regulations, or unexpected increases in our manufacturing costs; problems with
distribution of our products; and failure to adequately market our products.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The fact that our accounts payable are significant, and we
do not currently have sufficient funds to pay such accounts payable, a large portion of which are past due.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Risks from intense competition from companies with greater
resources and experience than we have.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to receive regulatory approvals for our product
candidates, and the timeline and costs associated therewith, including the uncertainties associated with the clinical development and
regulatory approval of our drug candidates, including potential delays in the enrollment and completion of clinical trials, issues raised
by the U.S. The Food and Drug Administration (FDA) and The Medicines and Healthcare products Regulatory Agency (MHRA).</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Risks that our future product candidates, if approved by regulatory
authorities, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from new
products.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The fact that the majority of our license agreements provide
the licensors and/or counter-parties the right to use, own and/or exploit such licensed intellectual property.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</div>
<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<div style="padding: 5; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Liability from lawsuits (including product liability lawsuits,
stockholder lawsuits and regulatory matters), including judgments, damages, fines and penalties and including the outcome of currently
pending litigation, potential future government investigations, and other proceedings that may adversely affect our business and results
of operations.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to comply with existing and future rules and regulations.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to adequately protect our proprietary technology
and intellectual property, claims and liability from third parties regarding our alleged infringement of their intellectual property.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The effect of current and future regulation, the Company&rsquo;s
ability to comply with regulations (both current and future) and potential penalties in the event it fails to comply with such regulations
and changes in the enforcement and interpretation of existing laws and regulations and the adoption of new laws and regulations that
may unfavorably impact our business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Failure of our information technology systems, including cybersecurity
attacks or other data security incidents, that could significantly disrupt the operation of our business.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The liquidation preference associated with, dilution caused
by the conversion of, and voting rights associated with, our Series B Convertible Preferred Stock.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The fact that we may acquire other companies which could divert
our management&rsquo;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our
operating results and if we make any acquisitions, they may disrupt or have a negative impact on our business.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The effect of changes in inflation and interest rates, and
economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts
of war (including the ongoing Ukraine/Russian and Hamas/Israel conflict)&nbsp;and other large-scale crises, as well as the potential
implications of a Congressional impasse over the U.S. debt limit or possible future U.S. governmental shutdowns over budget disagreements.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to maintain our listing of our common stock and
public warrants on the Nasdaq Capital Market, including our current non-compliance with Nasdaq&rsquo;s continued listing rules due to
our failure to maintain a majority of independent directors and an audit committee of at least three independent directors.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The reliance on suppliers of third-party gaming content and
the cost of such content.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The ability of the Company to obtain gaming licenses.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The Company&rsquo;s reliance on its management.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The ability of the Company to compete in the iGaming market.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The ability to compete against existing and new competitors.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The ability to manage expenses associated with sales and
marketing and necessary general and administrative and technology investments.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">General consumer sentiment and economic conditions that may
affect levels of discretionary customer purchases of the Company&rsquo;s products, including potential recessions and global economic
slowdowns.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">other risks and uncertainties, including those described
under, and incorporated by reference into, &ldquo;<U>Risk Factors</U>&rdquo;, below.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</div>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_003"></A>Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in shares of our
common stock involves a high degree of risk. Before making an investment decision, you should carefully consider and evaluate the risks
described in the &ldquo;<U>Risk Factors</U>&rdquo; section in our most recent Annual Report on Form 10-K, as well as any updates to those
risk factors in our subsequent Quarterly Reports on Form 10-Q, and below, together with all of the other information appearing in or incorporated
by reference into this prospectus, before deciding whether to purchase any of the common stock being offered. The risks described in these
documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic,
business, competitive, regulatory or other factors that could have material adverse effects on our future results. Our business, financial
condition or results of operations could be materially adversely affected by any of these risks. The trading price of shares of our common
stock could decline due to any of these risks, and you may lose all or part of your investment. Please also read carefully the section
entitled &ldquo;<I><U>Cautionary Note Regarding Forward-Looking Statements</U></I><U>.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Sales of substantial
amounts of our common stock by the&nbsp;selling stockholder, or the perception that these sales could occur, could adversely affect the
price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale by the selling stockholder
of a significant number of shares of common stock could have a material adverse effect on the market price of our common stock. In addition,
the perception in the public markets that the&nbsp;selling stockholder&nbsp;may sell all or a portion of its shares as a result of the
registration of such shares for&nbsp;resale&nbsp;pursuant to this prospectus could also in and of itself have a material adverse effect
on the market price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the
availability of those shares of common stock for sale will have on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><B><I>We currently have
an illiquid and volatile market for our common stock, and the market for our common stock is and may remain illiquid and volatile in the
future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have a highly
sporadic, illiquid and volatile market for our common stock, which market is anticipated to remain sporadic, illiquid and volatile in
the future. During the last 52 weeks our common stock has traded as high as $17.75 per share and as low as $1.16 per share. The market
price of our common stock may continue to be highly volatile and subject to wide fluctuations. Our financial performance, government regulatory
action, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;<U>short squeezes</U>&rdquo;;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">comments by securities analysts or other third parties, including
blogs, articles, message boards and social and other media;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">large stockholders exiting their position in our securities
or an increase or decrease in the short interest in our securities;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated fluctuations in our financial and operating
results;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in foreign currency exchange rates;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the commencement, enrollment or results of our planned or
future clinical trials of our product candidates or those of our competitors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the success of competitive drugs or therapies;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulatory or legal developments in the U.S. and other countries;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the success of competitive products or technologies;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">developments or disputes concerning patent applications,
issued patents or other proprietary rights;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the recruitment or departure of key personnel;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the level of expenses related to our iGaming operations,
product candidates or clinical development programs;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">litigation matters, including amounts which may or may not
be recoverable pursuant to our officer and director insurance policies, regulatory actions affecting the Company and the outcome thereof;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the results of our efforts to discover, develop, acquire
or in-license additional product candidates;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated changes in estimates as to financial
results, development timelines or recommendations by securities analysts;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our inability to obtain or delays in obtaining adequate drug
supply for any approved drug or inability to do so at acceptable prices;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">disputes or other developments relating to proprietary rights,
including patents, litigation matters and our ability to obtain patent protection for our technologies;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the timing and outcome of our plans to commercialize our
iGaming intellectual property;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">significant lawsuits, including patent or stockholder litigation;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">variations in our financial results or those of companies
that are perceived to be similar to us;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in the structure of healthcare payment systems, including
coverage and adequate reimbursement for any approved drug;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology
sectors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general economic, political, and market conditions and overall
fluctuations in the financial markets in the U.S. and abroad; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">investors&rsquo; general perception of us and our business.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;<FONT STYLE="background-color: white"><U>ATNF</U></FONT><U>.</U>&rdquo; Our stock
price may be impacted by factors that are unrelated or disproportionate to our operating performance. The stock markets in general have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market
fluctuations may adversely affect the trading price of our common stock. Additionally, general economic, political and market conditions,
such as recessions, inflation, war, interest rates or international currency fluctuations may adversely affect the market price of our
common stock. Due to the limited volume of our shares which trade, we believe that our stock prices (bid, ask and closing prices)&nbsp;may
not be related to our actual value, and not reflect the actual value of our common stock. You should exercise caution before making an
investment in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock markets in general and
our stock price in particular have recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of those companies and our company. For example, during 2022, the closing sales prices of our common stock
ranged from a post-split adjusted high of $1,482.04 per share to a low of $23.56 per share, during fiscal 2023, the closing sales prices
of our common stock ranged from a high of $100.70 per share to a low of $3.21 per share and during fiscal 2024 (through the date of this
prospectus), the closing sales prices of our common stock ranged from a post-split adjusted high of $6.47 per share to a low of $1.18
per share. During this time, we do not believe that we have experienced any material changes in our financial condition or results of
operations that would explain such price volatility or trading volume; however, we have sold equity which was dilutive to existing stockholders.
These broad market fluctuations may adversely affect the trading price of our securities. Additionally, these and other external factors
have caused and may continue to cause the market price and demand for our common stock to fluctuate substantially, which may limit or
prevent our stockholders from readily selling their shares of our common stock and may otherwise negatively affect the liquidity of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, as a result
of the illiquidity of our common stock, investors may not be interested in owning our common stock because of the inability to acquire
or sell a substantial block of our common stock at one time. Such illiquidity could have an adverse effect on the market price of our
common stock. In addition, a shareholder may not be able to borrow funds using our common stock as collateral because lenders may be unwilling
to accept the pledge of securities having such a limited market. An active trading market for our common stock may not develop or, if
one develops, may not be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, many companies
that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be
the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our
management&rsquo;s attention from other business concerns, which could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The exercise of the
outstanding options and warrants, and the sale of common stock upon exercise thereof, may adversely affect the trading price of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we had 22,891 shares of common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price of
$61.92 per share; (a)&nbsp;15,132 shares of common stock issuable upon the exercise of outstanding public warrants exercisable at an exercise
price of $4,370.00 per share, (b)&nbsp;6,748 shares of common stock issuable upon the exercise of certain outstanding private placement
warrants at an exercise price of $1,900.00 per share, (d)&nbsp;6,579 shares of common stock issuable upon the exercise of certain outstanding
private placement warrants at an exercise price of $2,850.00 per share, (e) 4,049 shares of common stock issuable upon exercise of certain
outstanding warrants to purchase shares of common stock with an exercise price of $3.23 per share, (f)&nbsp;3,000,000 shares of common
stock issuable upon the exercise of warrants to purchase 3,000,000 shares of common stock with an exercise price of $1.68 per share, (g)
168 shares of common stock issuable upon exercise of warrants which expire on May 2, 2025, and (h) 1,900,138 shares of common stock issuable
upon exercise of the October 2024 Warrants with an exercise price of $1.50 per share. For the life of the options and warrants, the holders
have the opportunity to profit from a rise in the market price of our common stock without assuming the risk of ownership. The issuance
of shares upon the exercise of outstanding securities will also dilute the ownership interests of our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The availability of these
shares for public resale, as well as any actual resales of these shares, could adversely affect the trading price of our common stock.
We cannot predict the size of future issuances of our common stock pursuant to the exercise of outstanding options or warrants or conversion
of other securities, or the effect, if any, that future issuances and sales of shares of our common stock may have on the market price
of our common stock. Sales or distributions of substantial amounts of our common stock (including shares issued in connection with an
acquisition), or the perception that such sales could occur, may cause the market price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the common stock
issuable upon exercise/conversion of outstanding convertible securities may represent overhang that may also adversely affect the market
price of our common stock. Overhang occurs when there is a greater supply of a company&rsquo;s stock in the market than there is demand
for that stock. When this happens the price of our stock will decrease, and any additional shares which stockholders attempt to sell in
the market will only further decrease the share price. If the share volume of our common stock cannot absorb shares sold by holders of
our outstanding convertible securities, then the value of our common stock will likely decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>There may not be sufficient
liquidity in the market for our securities in order for investors to sell their shares. The market price of our common stock may continue
to be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our common
stock will likely continue to be highly volatile. Some of the factors that may materially affect the market price of our common stock
are beyond our control, such as conditions or trends in the industry in which we operate or sales of our common stock. This situation
is attributable to a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts,
stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if
we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours
or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a consequence, there may
be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a mature issuer which
has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price.
It is possible that a broader or more active public trading market for our common stock will not develop or be sustained, or that trading
levels will not continue. These factors may materially adversely affect the market price of our common stock, regardless of our performance.
In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly
affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific
companies. These broad market fluctuations may adversely affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Stockholders may be
diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares of our
common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wherever possible, our Board
will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will
consist of restricted shares of our common stock or where shares are to be issued to our officers, directors and applicable consultants.
Our Board of Directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules and regulations (which generally
require stockholder approval for any transactions which would result in the issuance of more than 20% of our then outstanding shares of
common stock or voting rights representing over 20% of our then outstanding shares of stock, subject to certain exceptions), to issue
all or part of the authorized but unissued shares of common stock. In addition, we may attempt to raise capital by selling shares of our
common stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders,
which may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing
management&rsquo;s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting
existing management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_004"></A>Incorporation by
Reference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;<U>incorporate
by reference</U>&rdquo; into this prospectus the information in other documents that we file with it. This means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be a part
of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information contained
in documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference in this prospectus the documents
listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior
to the termination of the offering under this prospectus; provided, however, that we are not incorporating, in each case, any documents
or information deemed to have been furnished and not filed in accordance with SEC rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(a)</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024025262/ea0200233-10k_180lif.htm">Form 10-K</A>&nbsp;for the year ended December 31, 2023, filed with
    the SEC on March 25, 2024, as amended by <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024037176/ea0204622-10ka1_180life.htm">Amendment No. 1</A> thereto filed with the SEC on April 29, 2024&nbsp;(File No. 001-38105) (as
    amended, the &ldquo;<U>Annual Report</U>&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(b)</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024043746/ea0204921-10q_180life.htm">Form 10-Q</A> for the quarter ended March 31, 2024, filed with the SEC on May 15, 2024 (File No. 001-38105), the Company&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024067741/ea0210822-10q_180life.htm">Form 10-Q</A> for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024 and the Company&rsquo;s Quarterly Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1690080/000121390024098508/ea0220680-10q_180life.htm">Form 10-Q</A> for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024 (File No. 001-38105);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(c)</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1690080/000121390024096232/ea0220686-def14a_180life.htm">Schedule 14A</A>, filed with the Commission on November 12, 2024, to the extent filed and not furnished with the Commission;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Current Reports on Form 8-K (other than information furnished rather than filed)
    filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024003538/ea191607-8k_180life.htm">January
    16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024003899/ea191699-8k_180life.htm">January 17,
    2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024007176/ea192211-8k_180life.htm">January 29, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024014908/ea193928-8k_180life.htm">February
    16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024015102/ea193909-8k_180life.htm">February 20,
    2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024016681/ea0200627-8k_180life.htm">February 26,
    2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024017724/ea0200762-8k_180life.htm">February 28,
    2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024018231/ea0200917-8k_180life.htm">February 29,
    2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024019036/ea0200953-8k_180life.htm">March 1, 2024</A>,
    <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024021093/ea0201429-8k_180life.htm">March 8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024021213/ea0201449-8k_180life.htm">March 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024022381/ea0201776-8k_180life.htm">March 14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024034519/ea0204234-8k_180life.htm">April 19, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024041030/ea0205589-8k_180lifesci.htm">May 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024043761/ea0206133-8k_180lifesci.htm">May 15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024045652/ea020665801-8k_180life.htm">May 21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024058189/ea0208829-8k_180life.htm">July 2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000101376224000598/ea020982001-8k_180lifesci.htm">July 23, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000101376224002270/ea0210232-8k_180lifesci.htm">July 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024076949/ea0213868-8k_180life.htm">September 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024078158/ea0214322-8k_180life.htm">September 12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024084859/ea0216403-8k_180life.htm">October 3, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024086401/ea0217109-8k_180life.htm">October 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024087976/ea0217703-8k_180life.htm">October 16, 2024</A>,
    <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024088119/ea0217785-8k_180life.htm">October 16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024089354/ea0217938-8k_180life.htm">October 21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024091422/ea0218848-8k_180life.htm">October 29, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024091732/ea0218911-8k_180life.htm">October 29, 2024</A> (File No. 001-38105); and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(d)</TD>
    <TD STYLE="text-align: justify">The description of the Company&rsquo;s common stock contained in our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023025521/f10k2022_180lifesci.htm">Form
    10-K</A> for the year ended December 31, 2022, filed with the SEC on March 31, 2023, as <A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023025521/f10k2022ex4-6_180lifesci.htm">Exhibit 4.6</A> (File No.&nbsp;001-38105),
    including any amendment or report filed for the purpose of updating such description.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, all documents
filed by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the initial registration statement
of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) the date of this prospectus and
before the termination or completion of any offering hereunder, shall be deemed to be incorporated by reference into this prospectus from
the respective dates of filing of such documents, except that we do not incorporate any document or portion of a document that is &ldquo;<U>furnished</U>&rdquo;
to the SEC, but not deemed &ldquo;<U>filed.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide, without charge,
to each person to whom a copy of this prospectus is delivered, including any beneficial owner, upon the written or oral request of such
person, a copy of any or all of the documents incorporated by reference herein, including exhibits. Requests should be directed to: Attention:
Corporate Secretary, 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, telephone (650) 507-0669 .&nbsp;The documents
incorporated by reference may be accessed on the &ldquo;<U>Investors</U>&rdquo;&mdash;&rdquo;<U>SEC Filings</U>&rdquo;&mdash;&rdquo;<U>All
SEC Filings</U>&rdquo; page of our website at www.180lifesciences.com. We do not incorporate the information on our website into this
prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website
as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate
by reference into this prospectus or any supplement to this prospectus).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for
purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_005"></A>Cautionary Note
Regarding Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains forward-looking
statements under federal securities laws, including within the meaning of the Private Securities Litigation Reform Act&nbsp;of&nbsp;1995.
In some cases, you can identify forward-looking statements by the following words: &ldquo;<U>anticipate,</U>&rdquo; &ldquo;<U>believe,</U>&rdquo;
&ldquo;<U>continue,</U>&rdquo; &ldquo;<U>could,</U>&rdquo; &ldquo;<U>estimate,</U>&rdquo; &ldquo;<U>expect,</U>&rdquo; &ldquo;<U>intend,</U>&rdquo;
&ldquo;<U>may,</U>&rdquo; &ldquo;<U>ongoing,</U>&rdquo; &ldquo;<U>plan,</U>&rdquo; &ldquo;<U>potential,</U>&rdquo; &ldquo;<U>predict,</U>&rdquo;
&ldquo;<U>project,</U>&rdquo; &ldquo;<U>should,</U>&rdquo; or the negative of these terms or other comparable terminology, although not
all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and
will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking
statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and
other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by the forward-looking statements in this prospectus, including those incorporated by reference into the section
entitled &ldquo;<I><U>Risk Factors</U></I>&rdquo; herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, forward-looking
statements include, but are not limited to, any statements that are not statements of current or historical facts, such as statements
relating to our expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of
our product candidates, the accuracy of our estimates regarding expenses, future revenues and capital requirements, our ability to execute
our plans to develop and market new drug products and the timing and costs of these development programs, and estimates of the sufficiency
of our existing capital resources combined with future anticipated cash flows to finance our operating requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such statements are based
on management&rsquo;s current expectations and include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The need for additional funding, our ability to raise funding
in the future, the terms of such funding, and dilution caused thereby;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to create or purchase a front end for our back
end blockchain casino intellectual property assets, commercialize our planned blockchain casino, obtain required licenses and customers,
and come to mutually agreeable contractual terms with third parties and suppliers, and ultimately generate revenues through such operations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">expectations for the clinical and preclinical development,
manufacturing, regulatory approval, and commercialization of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the uncertainties associated with the clinical development
and regulatory approval of the Company&rsquo;s drug candidates, including potential delays in the enrollment and completion of clinical
trials, issues raised by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the U.K. Medicines and
Healthcare products Regulatory Agency (MHRA);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulatory developments in the United States and foreign
countries;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our success in retaining or recruiting, or changes required
in, our officers, key employees or directors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">current negative operating cash flows and our potential ability
to obtain additional financing to advance our business and the terms of any further financing, which may be highly dilutive and may include
onerous terms;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the continued impact of the COVID-19 pandemic on our business
operations and our research and development initiatives;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the accuracy of our estimates regarding expenses, future
revenues and capital requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s reliance on third parties to conduct
its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies, the ability to come to mutually agreeable
terms with such third parties and partners, and the terms of such agreements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the terms of the Company&rsquo;s current licensing agreements,
and the termination rights associated therewith;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">estimates of patient populations for the Company&rsquo;s
planned products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">unexpected adverse side effects or inadequate therapeutic
efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability
claims;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to fully comply with numerous
federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to
its product development activities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">challenges and uncertainties inherent in product research
and development, including the uncertainty of clinical success and of obtaining regulatory approvals; and uncertainty of commercial success;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability of the Company to execute its plans to develop
and market new drug products and the timing and costs of these development programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changing rates of inflation and interest rates, and economic
downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war
(including the ongoing Ukraine/Russian conflict, and Israel/Hamas conflict) and other large-scale crises;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">estimates of the sufficiency of our existing capital resources
combined with future anticipated cash flows to finance our operating requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the review and evaluation of strategic transactions and their
impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential
future strategic transactions and the terms thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain our listing of our common stock and
public warrants on the Nasdaq Capital Market, including our current non-compliance with Nasdaq&rsquo;s continued listing rules due to
our failure to maintain a majority of independent directors and an audit committee of at least three independent directors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the reliance on suppliers of third-party gaming content and
the cost of such content;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability of the Company to obtain gaming licenses;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s reliance on its management;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the potential effect of economic downturns, recessions, changes
in interest rates and inflation, and market conditions, including recessions, decreases in discretionary spending and therefore demand
for our products, and increases in the cost of capital, related thereto, among other affects thereof, on the Company&rsquo;s operations
and prospects as a result of increased inflation, increasing interest rates, global conflicts and other events;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to protect its proprietary information
and intellectual property (IP);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability of the Company to compete in the iGaming market;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the effect of current and future regulation, the Company&rsquo;s
ability to comply with regulations (both current and future) and potential penalties in the event it fails to comply with such regulations
and changes in the enforcement and interpretation of existing laws and regulations and the adoption of new laws and regulations that
may unfavorably impact our business;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability to compete against existing and new competitors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability to manage expenses associated with sales and
marketing and necessary general and administrative and technology investments;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general consumer sentiment and economic conditions that may
affect levels of discretionary customer purchases of the Company&rsquo;s products, including potential recessions and global economic
slowdowns; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">other risks and uncertainties, including those described
under &ldquo;<I><U>Risk Factors</U></I>&rdquo;, herein.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any forward-looking statements
in this prospectus reflect our current views with respect to future events or to our future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. All forward-looking statements included herein speak only as
of the date of this prospectus. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our
behalf, are expressly qualified in their entirety by the cautionary statements above. Except as required by law, we assume no obligation
to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_006"></A>Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any of
the proceeds from the sale by the Selling Stockholder of the Shares in this offering. However, if all of the Warrants that are covered
by this prospectus are exercised for cash, we may receive proceeds of up to approximately $2,850,207. We cannot predict when, or if, the
Warrants will be exercised. It is possible that the Warrants may expire and may never be exercised for cash. We intend to use any proceeds
from the exercise of the Warrants for operationalizing and developing our recently acquired Technology Gaming Platform, and general corporate
and legal expenses. Our management will have broad discretion over the use of proceeds from the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder will
pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholder for brokerage, accounting, tax or legal
services or any other expenses incurred by the Selling Stockholder in disposing of the Shares. We will bear all other costs, fees and
expenses incurred in effecting the registration of the Shares covered by this prospectus, including all registration and filing fees,
and fees and expenses of our counsel and our independent registered public accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_007"></A>Dividend Policy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid or declared
any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. We anticipate that we will
retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay
dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common
stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_008"></A>Beneficial Ownership
of Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Security Ownership of Management and Certain
Beneficial Owners and Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table contains
information regarding the beneficial ownership of our voting stock as of November 15, 2024 (the &ldquo;<U>Date of Determination</U>&rdquo;),
held by (i)&nbsp;each stockholder known by us to beneficially own more than 5% of the outstanding shares of any class of voting stock;
(ii)&nbsp;our directors; (iii)&nbsp;our Named Executive Officers as defined in the Summary Executive Compensation Table of our Annual
Report on Form 10-K for the year ended December 31, 2023, which is incorporated by reference herein; and (iv)&nbsp;all current directors
and executive officers as a group. Except where noted, all holders listed below have sole voting power and investment power over the shares
beneficially owned by them. Unless otherwise noted, the address of each person listed below is c/o 180 Life Sciences Corp., 3000 El Camino
Real, Bldg. 4, Suite 200, Palo Alto, California 94306.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership has been
determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned
by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares
are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an option
or warrant or upon conversion of a convertible security)&nbsp;within 60 days of the date as of which the information is provided. In computing
the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person
by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table
does not necessarily reflect the person&rsquo;s actual voting power at any particular date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership as set
forth below is based on our review of our record stockholders list and public ownership reports filed by certain of our stockholders,
and may not include certain securities held in brokerage accounts or beneficially owned by the stockholders described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owners</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Common<BR> Stock Shares<BR> Beneficially<BR> Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of<BR> Common<BR> Stock**</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Directors, Executive Officers and Named Executive Officers</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Blair Jordan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Omar Jimenez</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ryan Smith</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jay Goodman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Lawrence Steinman</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,389</TD><TD STYLE="width: 1%; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">*</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">James N.&nbsp;Woody<SUP>&pound;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Jonathan Rothbard<SUP>&pound;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,475</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Quan Anh Vu<SUP>&pound;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Ozan Pamir<SUP>&pound;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">*</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">All officers and directors as a group (5 persons)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,389</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">5% Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>None.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than one percent.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Percentages based upon 1,976,999 shares of our common stock
issued and outstanding at November 15, 2024.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>&pound;</SUP></TD><TD STYLE="text-align: justify">Former Named Executive Officer, no longer serving as an officer
or director of the Company. Beneficial ownership is based on either (a) the last beneficial ownership disclosed to the Company from such
persons; or (b) the record shareholders list of the Company as of the Date of Determination, and may not reflect the total number of
shares of common stock of the Company beneficially owned by the noted individual as of such date.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes options to purchase 65&nbsp;shares of common stock
at an exercise price of $1,501.00 per share and options to purchase 789 shares of common stock with an exercise price of $12.73 per share,
which have vested, and/or which vest within 60&nbsp;days of the Date of Determination.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes options to purchase 473&nbsp;shares of common stock
at an exercise price of $1,683.40 per share and options to purchase 789 shares of common stock with an exercise price of $12.73 per share,
which have vested, and/or which vest within 60&nbsp;days of the Date of Determination, and which expire if unexercised on December 30,
2024.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Change of Control</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is not aware of
any arrangements which may at a subsequent date result in a change of control of the Company, except that at such time as the shareholders
of the Company have approved the issuance of shares of common stock upon conversion of our 1,000,000 shares of outstanding Series B Convertible
Preferred Stock, if ever, such shares of Series B Convertible Preferred Stock currently held by El Ray Resources, Inc., will be convertible
into 40% of outstanding shares of common stock (subject to a maximum of 10 million shares), at the time of such stockholder approval &nbsp;(66.7%
of the Company&rsquo;s pre-issuance outstanding shares of common stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_009"></A>Selling Stockholder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Shares being offered by
the Selling Stockholder consist of 1,900,138 shares of common stock issuable upon the exercise of the October 2024 Common Warrants, see
the section entitled &ldquo;<I><U>Prospectus Summary&mdash;Warrants and Related Transactions</U></I>&rdquo;, above. We are registering
the Shares in order to permit the Selling Stockholder to offer the Shares for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
Selling Stockholder and other information regarding the beneficial ownership of the shares of our common stock by the Selling Stockholder.
The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on its ownership of
the shares of common stock and Warrants, as of November 15, 2024, assuming exercise of the Warrants held by the Selling Stockholder on
that date, if any, without regard to any limitations on exercises. The third column lists the shares of common stock being offered by
this prospectus by the Selling Stockholder. The fourth column assumes the sale of all of the Shares offered by the Selling Stockholder
pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of each of
the Warrants, the Selling Stockholder may not exercise the warrants to the extent such exercise would cause the Selling Stockholder, together
with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%, of our then
outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise
of such Warrants which have not been exercised. The number of shares of common stock in the second and fourth columns do not reflect this
limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder may
sell all, some or none of their Shares in this offering. See &ldquo;<I><U>Plan of Distribution</U></I><U>.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Number of Shares of Common<BR> Stock Beneficially Owned<BR> Prior to this Offering&nbsp;<SUP>(1)(2)</SUP></B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of<BR> Shares of<BR> Common<BR> Stock&nbsp;Being</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Beneficial Ownership of<BR> Common Stock After this<BR> Offering&nbsp;<SUP>(2)</SUP></B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Offered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Armistice Capital, LLC<SUP>(3)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,900,138</TD><TD STYLE="vertical-align: top; white-space: nowrap; width: 1%; text-align: left"><SUP>(3)</SUP>&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.99</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%<SUP>(3)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,900,138</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left"><SUP>(6)</SUP>&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 1%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify">&ldquo;<U>Beneficial ownership</U>&rdquo; means that a person,
directly or indirectly, has or shares voting or investment power with respect to a security or has the right to acquire such power within
60 days.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="text-align: justify">Assumes for purposes of the &ldquo;<U>Beneficial Ownership
of Common Stock After this Offering</U>&rdquo; that (i) all of the shares of common stock to be registered by the registration statement
of which this prospectus is a part are sold in this offering and (ii)&nbsp;the selling stockholder does not acquire additional shares
of our common stock after the date of this prospectus and prior to completion of this offering.&nbsp;The registration of this offering
of shares does not necessarily mean that the selling stockholders will sell all or any portion of the shares covered by this prospectus.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="text-align: justify">The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the
&ldquo;Master Fund&rdquo;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&ldquo;Armistice Capital&rdquo;),
as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. &nbsp;The warrants are
subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion
of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock
in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510
Madison Avenue, 7th Floor, New York, NY 10022.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="text-align: justify">Represents shares of common stock equal to 4.99% of the Company&rsquo;s
outstanding common stock following the issuance thereof, as a result of the beneficial ownership limitation.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="text-align: justify">The shares of common stock being offered pursuant to this
prospectus consist of 1,900,138 shares of common stock issuable upon the exercise of the October 2024 Common Warrants.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_010"></A>Plan of Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder and
any of its pledgees, assignees, transferees and successors-in-interest may, from time to time, sell any or all of the Shares covered hereby
on Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These
sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which
the broker-dealer solicits purchasers;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell
the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of the
applicable exchange;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">settlement of short sales;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">in transactions through broker-dealers that agree with the
Selling Stockholder to sell a specified number of such securities at a stipulated price per security;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a combination of any such methods of sale; or</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder may
also sell the Shares under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)&nbsp;in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the Shares or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The Selling Stockholder
may also sell the Shares short and deliver the Shares to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell the Shares. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other
financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial
institution of the Shares offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuant
to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder and
any broker-dealers or agents that are involved in selling the Shares may be deemed to be &ldquo;<U>underwriters</U>&rdquo; within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to pay certain
fees and expenses incurred by us incident to the registration of the Shares. We have agreed to indemnify the Selling Stockholder against
certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to keep this prospectus
effective until all of the Shares underlying the Warrants have been sold pursuant to this prospectus or Rule 144 under the Securities
Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and
regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder
or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed it of the need to deliver
a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities
Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_011"></A>Description of
Capital Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary of
the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities. We
urge you to read our Certificate of Incorporation, as amended in its entirety, for a complete description of the rights and preferences
of our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we have 100,000,000 authorized shares of common stock, $0.0001 par value per share and 5,000,000 shares of preferred stock, $0.0001 par
value per share, of which 1,000,000 shares have been designated as Series A Convertible Preferred Stock (of which none are outstanding),
of which one share of preferred stock has been designated as a Class C Special Voting Share, of which none are outstanding, and one share
of preferred stock has been designated as a Class K Special Voting Share, of which none are outstanding, and of which 1,000,000 shares
have been designated as Series B Convertible Preferred Stock, of which 1,000,000 shares are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the date of this prospectus,
there were 1,976,999 shares of common stock outstanding held by 122 holders of record, and 1,000,000 shares of Series B Convertible Preferred
Stock issued or outstanding, held by one holder of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise required
by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of our common stock possess
all voting power for the election of our directors and all other matters requiring stockholder action and will at all times vote together
as one class on all matters submitted to a vote of our stockholders. Holders of common stock are entitled to one vote per share on matters
to be voted on by stockholders and do not have the right to cumulate votes in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock will
be entitled to receive dividends and other distributions, if any, in amounts declared from time to time by our Board of Directors in its
discretion out of funds legally available therefor and shall share equally on a per share basis in these dividends and distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our
voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled
to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders, after the rights
of the holders of the preferred stock, if any, have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our stockholders have no preemptive
or other subscription rights and there are no sinking fund or redemption provisions applicable to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is
divided into two classes, with only one class of directors being elected in each year and each class generally serving a two-year term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides that shares of preferred stock may be issued from time to time in one or more series. Our Board of Directors will be authorized
to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and
any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board of Directors will be able
to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and
other rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board of Directors to issue preferred
stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of the Company or the
removal of existing management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Series B Convertible
Preferred Stock</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The below is a summary of the rights
and preferences of the Series B Convertible Preferred Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting Rights</I>. Until
such time, if ever, as the stockholders of the Company have approved the issuance of shares of common stock upon the conversion of the
Series B Convertible Preferred Stock (&ldquo;<U>Stockholder Approval</U>&rdquo;), the Series B Convertible Preferred Stock only has rights
to vote on amendments to the Series B Designation (which are subject to the approval of a simple majority of the holders of Series B Convertible
Preferred Stock), and the Protective Provisions, discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series B Preferred Stock
require the consent of the holders of at least a majority of the issued and outstanding shares of Series B Convertible Preferred Stock
to (a)&nbsp;increase or decrease (other than by redemption or conversion)&nbsp;the total number of authorized shares of Series B Convertible
Preferred Stock of the Company; (b)&nbsp;adopt or authorize any new designation of any Preferred Stock or amend the Certificate of Incorporation
of the Company in a manner which (i)&nbsp;provides any holder of common stock or preferred stock any rights upon a liquidation of the
Company which are prior and superior to those of the holders of the Series B Convertible Preferred Stock; or (ii)&nbsp;adversely affect
the rights, preferences and privileges of the Series B Convertible Preferred Stock; (c)&nbsp;effect an exchange, or create a right of
exchange, cancel, or create a right to cancel, of all or any part of the shares of another class of shares into shares of Series B Convertible
Preferred Stock; (d)&nbsp;alter or change the rights, preferences or privileges of the shares of Series B Convertible Preferred Stock
so as to affect adversely the shares of such series; and (e)&nbsp;issue any shares of Series A Preferred Stock or Series B Convertible
Preferred Stock, other than the 1,000,000 shares of Series B Preferred Stock currently outstanding (collectively, the &ldquo;<U>Protective
Provisions</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After Stockholder Approval,
in addition to the above voting rights, each holder of outstanding shares of Series B Convertible Preferred Stock shall be entitled to
cast the number of votes in connection with the Series B Convertible Preferred Stock shares held by such holder equal to the number of
whole shares of common stock into which the shares of Series B Convertible Preferred Stock held by such holder are convertible as of the
record date for determining stockholders entitled to vote on such matter. Fractional votes shall not, however, be permitted and any fractional
voting rights available on an as-converted to common stock basis (after aggregating all fractional shares into which shares of Series
B Convertible Preferred Stock held by each holder could be converted)&nbsp;shall be rounded down to the nearest whole share. Except as
provided by law or by the other provisions of the Certificate of Incorporation or the Series B Designation, holders of Series B Convertible
Preferred Stock shall vote together with the holders of common stock as a single class and there shall be no series voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividend Rights</I>. None,
except that if the Company declares a dividend or makes a distribution of cash (or any other distribution treated as a dividend under
Section 301 of the Internal Revenue Code)&nbsp;on its common stock, each holder of Shares of Series B Convertible Preferred Stock is entitled
to participate in such dividend or distribution in an amount equal to the largest number of whole shares of common stock into which all
shares of Series B Convertible Preferred Stock held of record by such holder are convertible as of the record date for such dividend or
distribution or, if there is no specified record date, as of the date of such dividend or distribution. Notwithstanding the foregoing,
holders shall have no right of participation in connection with dividends or distributions made to the common stock stockholders consisting
solely of shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Preference</I>.
In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each a &ldquo;<U>Liquidation
Event</U>&rdquo;), the holders of Series B Convertible Preferred Stock are entitled to receive prior and in preference to any distribution
of any of the assets of the Company to the holders of the common stock or securities junior to the Series B Convertible Preferred Stock
(other than the common stock)&nbsp;by reason of their ownership of such stock, but after any required distribution to any holders of Series
B Convertible Preferred Stock, an amount in cash per share of Series B Convertible Preferred Stock for each share of Series B Convertible
Preferred Stock held by them equal to the greater of (x)&nbsp;one times the Stated Value; and (y)&nbsp;the total amount of consideration
that would have been payable on such share upon a Liquidation Event, had such share of Series B Convertible Preferred Stock been converted
into common stock, immediately prior to such Liquidation Event (as applicable, the &ldquo;<U>Liquidation Preference</U>&rdquo;). The &ldquo;<U>Stated
Value</U>&rdquo; is $17.30 per share of Series B Convertible Preferred Stock, for a total aggregate Liquidation Preference of $17,300,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Conversion Rights</I>.
None prior to Stockholder Approval. After Stockholder Approval, at the option of the holder(s)&nbsp;thereof, each share of Series B Convertible
Preferred Stock is convertible into a number of shares of common stock of the Company as equals the Conversion Rate. The &ldquo;<U>Conversion
Rate</U>&rdquo; shall initially be 0.685 (or 685,000 shares in aggregate, which would represent 40% of the Company&rsquo;s then outstanding
shares of common stock (66.7% of the Company&rsquo;s pre-issuance outstanding shares of common stock)), as equitably adjusted, as applicable
for stock splits and recapitalizations; provided that if at any time after the original issuance date of the Series B Convertible Preferred
Stock and prior to the Stockholder Approval Date, the Company shall actually issue any additional shares of common stock of the Company
(each a &ldquo;<U>Dilutive Issuance</U>&rdquo;), the Conversion Rate shall be increased to a value equal to (x)(i)&nbsp;the total outstanding
shares of common stock (&ldquo;<U>Total Outstanding Shares</U>&rdquo;)&nbsp;on the date immediately following such Dilutive Issuance,
divided by (ii)&nbsp;60%, minus (iii)&nbsp;the Total Outstanding Shares on the date immediately following such Dilutive Issuance, divided
by (y)&nbsp;1,000,000, rounded to the thousands place, as equitably adjusted, as applicable for stock splits and recapitalizations (each
a &ldquo;<U>Dilutive Adjustment</U>&rdquo;); provided that in no event will the Conversion Rate be greater than ten. The effect of any
change in the Conversion Rate shall not be retroactive and shall only apply for conversions of Series B Convertible Preferred Stock following
the date of any Dilutive Adjustment. The Conversion Rate is fixed at the time of Stockholder Approval and is not subject to further adjustment
thereafter. The Conversion Rate is designed to result in the holders of the Series B Convertible Preferred Stock receiving 40% of the
then outstanding shares of common stock upon conversion of the Series B Convertible Preferred Stock (66.7% of the Company&rsquo;s pre-issuance
outstanding shares of common stock), subject to a maximum of 10 million shares of common stock, and further subject to such conversion
ratio being fixed upon Stockholder Approval. The Conversion Rate is 1.318 or 1,318,000 total shares of common stock in aggregate as of
the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Redemption Rights</I>.
None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Stock Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is currently
listed on Nasdaq under the symbol &ldquo;<U>ATNF</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Stock Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Continental Stock Transfer &amp; Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain Anti-Takeover Provisions of Delaware
Law and our Certificate of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the provisions
of Section 203 of the Delaware General Corporation Law (the &ldquo;<U>DGCL</U>&rdquo;) regulating corporate takeovers. This statute prevents
certain Delaware corporations, under certain circumstances, from engaging in a &ldquo;<U>business combination</U>&rdquo; with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a stockholder who owns 15% or more of our outstanding voting
stock (otherwise known as an &ldquo;<U>interested stockholder</U>&rdquo;);</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an affiliate of an interested stockholder; or</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an associate of an interested stockholder, for three years
following the date that the stockholder became an interested stockholder.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &ldquo;<U>business combination</U>&rdquo;
includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Board of Directors approves the transaction that made
the stockholder an &ldquo;<U>interested stockholder,</U>&rdquo; prior to the date of the transaction;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">after the completion of the transaction that resulted in the
stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction
commenced, other than statutorily excluded shares of common stock; or</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">on or subsequent to the date of the transaction, the business
combination is approved by our Board of Directors and authorized at a meeting of our stockholders, and not by written consent, by an
affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides that our Board of Directors be classified into two classes of directors. As a result, in most circumstances, a person can gain
control of our Board of Directors only by successfully engaging in a proxy contest at two or more annual meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized but unissued
common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of
corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of
authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain
control of us by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities Eligible for Future Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Rule 144</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Rule 144, a person
who has beneficially owned restricted shares of our common stock or warrants for at least six months would be entitled to sell their securities
provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months
preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three months before the
sale and have filed all required reports under Section 13 or 15(d)&nbsp;of the Exchange Act during the 12 months (or such shorter period
as we were required to file reports)&nbsp;preceding the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Persons who have beneficially
owned restricted shares of our common stock or warrants for at least six months but who are our affiliates at the time of, or at any time
during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell
within any three-month period only a number of securities that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1% of the total number of shares of common stock then outstanding;
or</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the average weekly reported trading volume of the common stock
during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales by our affiliates under
Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Restrictions on the
Use of Rule 144 by Shell Companies or Former Shell Companies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 144 is not available
for the resale of securities initially issued by shell companies (other than business combination related shell companies)&nbsp;or issuers
that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the
following conditions are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the issuer of the securities that was formerly a shell company
has ceased to be a shell company;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the issuer of the securities is subject to the reporting requirements
of Section 13 or 15(d)&nbsp;of the Exchange Act;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the issuer of the securities has filed all Exchange Act reports
and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required
to file such reports and materials), other than Form 8-K reports; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at least one year has elapsed from the time that the issuer
filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_012"></A>Legal Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered by this prospectus have been passed upon for us by The Loev Law Firm, PC. David M. Loev, the President and sole owner of The Loev
Law Firm, PC, beneficially owns less than 1% of the outstanding shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_013"></A>Experts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of 180 Life Sciences Corp. and subsidiaries as of December 31, 2023 and 2022, and for each of the years in the two-year period
ended December 31, 2023, are incorporated into this prospectus by reference from 180 Life Science Corp.&rsquo;s Annual Report on Form
10-K for the year ended December 31, 2023, have been audited by Marcum LLP, an independent registered public accounting firm, as set forth
in their report thereon, incorporated herein by reference, and have been incorporated in this prospectus and Registration Statement in
reliance upon such reports given on the authority of such firm as an expert in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No expert or counsel named
in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities
being registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency
basis, or had, or is to receive, any interest, directly or indirectly, in our Company or any of our parents or subsidiaries, nor was any
such person connected with us or any of our parents or subsidiaries, if any, as a promoter, managing or principal underwriter, voting
trustee, director, officer, or employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_014"></A>Where You Can Find
More Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet
at the SEC&rsquo;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available, free of charge,
on our website at www.180lifesciences.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the SEC. This prospectus omits some information contained in the registration statement in
accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information
about us and our subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an
exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by
reference to these filings. You should review the complete document to evaluate these statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II<BR>
INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the common
stock being registered. All the amounts shown are estimates except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">268</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Miscellaneous fees and expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"></TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"></TD><TD STYLE="text-align: left">*</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Estimated fees and expenses not presently known.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the DGCL authorizes
a court to award, or a corporation&rsquo;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad
to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our
bylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have entered
into indemnification agreements with directors, officers and some employees containing provisions that are in some respects broader than
the specific indemnification provisions contained in the DGCL. The indemnification agreements will require us, among other things, to
indemnify our directors against certain liabilities that may arise by reason of their status or service as directors and to advance their
expenses incurred as a result of any proceeding against them as to which they could be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2023, we entered
into a placement agent agreement with A.G.P. On April 5, 2023, in connection with the placement agent agreement, we also entered into
a securities purchase agreement pursuant to which we issued and sold, in a private placement, warrants to purchase up to 82,668 shares
of our common stock at a purchase price per share of $36.29 (when including shares of common stock and pre-funded warrants to purchase
shares of common stock in a registered direct offering)&nbsp;in the concurrent private placement. The offering closed on April 10, 2023.
The net proceeds to us from the offering was approximately $2.7 million, after deducting placement agent fees and expenses and estimated
offering expenses payable by us. We issued the warrants to purchase up to 82,668 shares of our common stock without registration under
the Securities Act, based on the exemption from registration afforded by Section 4(a)(2)&nbsp;thereof and/or Rule 506(b)&nbsp;of Regulation
D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 28, 2023, the
Company entered into Amendment No. 1 to the August SPA with a certain institutional investor (the &ldquo;<U>Purchaser</U>&rdquo;)(the
&ldquo;<U>December 2023 SPA Amendment</U>&rdquo;), pursuant to which (i) the Purchaser agreed to pay an additional $830,769.30 in connection
with the repricing of the August 2023 Shares and August 2023 Pre-Funded Warrants (the &ldquo;<U>Repricing Amount</U>&rdquo;), (ii) the
Company agreed to issue to the Purchaser (x) pre-funded warrants to purchase up to 257,205 shares of common stock, with an exercise price
of $0.0001 per share (the &ldquo;<U>December 2023 Pre-Funded Warrants</U>&rdquo;), and (y) warrants to purchase up to 477,058 shares of
common stock, with an exercise price of $0.17 per share (the &ldquo;<U>December 2023 Common Warrants</U>&rdquo; and, together with the
December 2023 Pre-Funded Warrants, the &ldquo;<U>December 2023 Warrants</U>&rdquo;), and (iii) the Company and the Purchaser agreed to
enter into the Warrant Amendment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the December
2023 SPA Amendment, the Company entered into a warrant amendment agreement with the Purchaser, dated November 28, 2023 (the &ldquo;<U>December
2023 Warrant Amendment Agreement</U>&rdquo;), whereby the Company agreed to amend the following outstanding warrants held by the Purchaser:
(i) warrants to purchase up to 135,339 shares of common stock, issued on December 22, 2022, and amended in January 2023, April 2023 and
August 2023; (ii) warrants to purchase up to 16,138 shares of common stock, issued on July 20, 2022 and amended in April 2023 and August
2023; (iii) warrants to purchase up to 82,668 shares of common stock, issued on April 10, 2023 and August 2023; and (iv)&nbsp;warrants
to purchase up to 242,915 shares of common stock underlying the August Common Warrants (collectively, the &ldquo;<U>Existing Common Warrants</U>&rdquo;).
Pursuant to the Warrant Amendment Agreement, the Existing Common Warrants were amended (the &ldquo;<U>December 2023 Warrant Amendment</U>&rdquo;)
to not be exercisable until the Company obtained stockholder approval for the issuance of up to 477,058 shares of common stock upon exercise
of the Existing Common Warrants (the &ldquo;<U>Existing Common Warrant Shares</U>&rdquo;), which stockholder approval was received on
February 16, 2024. Pursuant to the December 2023 Warrant Agreement, the Existing Common Warrants were amended to have an exercise price
of $3.23 per share, and to expire on the fifth anniversary of the date that the stockholders of the Company approved the issuance of shares
of common stock upon exercise of such Existing Common Warrants, which stockholder approval date, which was February 16, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants and the warrant
shares have not been registered under the Securities Act, and were instead offered pursuant to the exemption provided in Section 4(a)(2)
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21, 2024, February
28, 2024, March 6, 2024 and March 7, 2024, the holder of pre-funded warrants to purchase shares of common stock of the Company at an exercise
price of $0.0019 per share, exercised warrants to purchase 58,520, 64,684, 72,000 and 62,000 shares of common stock, respectively, for
$111.19, $122.90, $136.80 and $117.80 of cash, respectively, and was issued 58,520, 64,684, 72,000 and 62,000 shares of common stock upon
exercise thereof, respectively. The exercise of the warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 12, 2024, a holder
of Class K Special Voting Shares converted such shares into 14 shares of common stock of the Company in a transaction exempt from registration
pursuant to Section 3(a)(9) of the Securities Act. As a result of such conversion, there are no longer any Class K Special Voting Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2024, we
closed the transactions contemplated by that certain September 29, 2024, Asset Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;)&nbsp;with
Elray Resources, Inc. (&ldquo;<U>Elray</U>&rdquo;), pursuant to which we acquired certain source code and intellectual property relating
to an online blockchain casino in consideration for 1,000,000 shares of newly designated Series B Convertible Preferred Stock (the &ldquo;<U>Preferred
Stock</U>&rdquo;)&nbsp;and warrants to purchase 3,000,000 shares of common stock of the Company (the &ldquo;<U>Warrants</U>&rdquo;). The
offer and sale of the Preferred Stock and the Warrants were intended to be exempt from registration pursuant to Section 4(a)(2) and/or
Rule 506 of Regulation D of the Securities Act, since the foregoing offer, sales and issuances did not involve a public offering, the
recipient confirmed that it was an &ldquo;<U>accredited investor</U>&rdquo;, and the recipient acquired the securities for investment
only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered
without any general solicitation by us or our representatives. The securities are subject to transfer restrictions, and the certificates
evidencing the securities will contain an appropriate legend stating that such securities have not been registered under the Securities
Act and may not be offered or sold absent registration or pursuant to an exemption therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 17, 2024, the Company issued the Holder the October 2024 Warrants to purchase up to 1,900,138 shares of common stock with an
exercise price of $1.50 per share pursuant to the terms of an Inducement Agreement dated October 16, 2024. The October 2024 Warrants
were immediately exercisable and have a term of exercise of five years. The Company claims an exemption from registration pursuant to
Section 4(a)(2) and/or Rule 506 of the Securities Act for the issuance of the October 2024 Warrants since the foregoing issuance did
not involve a public offering, the recipient took the securities for investment and not resale, we took appropriate measures to restrict
transfer, and the recipient was an accredited investor. The securities are subject to transfer restrictions, and the securities contain
an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent
registration or pursuant to an exemption therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><B>No.</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; width: 90%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>1.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023028603/ea176691ex1-1_180lifesci.htm">Placement Agent Agreement, dated April 5, 2023, between 180 Life Sciences Corp. and A.G.P./Alliance Global Partners (filed as Exhibit 1.1 to the registrant&rsquo;s Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>1.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/ea183547ex1-1_180life.htm">Placement Agency Agreement, dated August 9, 2023, by and between 180 Life Sciences Corp. and A.G.P./Alliance Global Partners. (filed as Exhibit 1.1 to the registrant&rsquo;s Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.1&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024084859/ea021640301ex2-1_180life.htm">Asset Purchase Agreement dated September 29, 2024, by and among Elray Resources, Inc., as seller and 180 Life Sciences Corp., as purchaser (filed as Exhibit 2.1 to the registrant&rsquo;s Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020036383/ea129454ex3-1_180lifesci.htm">Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K filed on November 12, 2020 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022080304/ea170293ex3-1_180lifesci.htm">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of Delaware on December 15, 2022 (filed as Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K filed on December 16, 2022 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024017724/ea0200762ex3-1_180life.htm">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of 180 Life Sciences Corp., filed with the Secretary of State of Delaware on February 26, 2024 (Filed as Exhibit 3.1 To the Current Report on Form 8-K filed by the registrant on February 28, 2024, and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1690080/000121390024084859/ea021640301ex3-1_180life.htm">Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023074568/ea184802ex3-1_180life.htm">Second Amended and Restated&nbsp;Bylaws of 180 Life Sciences Corp., effective as of September 4, 2023&nbsp;(filed as10.39# Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K filed on September 7, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390017004247/fs12017ex4ii_kplmerger.htm">Specimen Common Stock Certificate (filed as Exhibit 4.2 to the registrant&rsquo;s Registration Statement Form S-1 filed on April 26, 2017 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023025521/f10k2022ex4-6_180lifesci.htm">Description of the Registrant&rsquo;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (filed as Exhibit 4.6 to the registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 31, 2023 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022040292/ea163025ex4-2_180life.htm">Form of July Common Warrant (filed as Exhibit 4.2 to the registrant&rsquo;s Current Report on Form 8-K filed on July 19, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022082245/ea170740ex4-2_180life.htm">Form of December Common Warrant (filed as Exhibit 4.2 to the registrant&rsquo;s Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023002524/ea171610ex4-1_180lifesci.htm">Amendment No. 1 to the December 2022 Common Warrants, dated January 12, 2023, by and between 180 Life Sciences Corp. and the Selling Stockholder (filed as Exhibit 4.1 to the registrant&rsquo;s Current Report on Form 8-K filed on January 12, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023039786/f10q0323ex10-11_180lifesci.htm">Amendment No. 1 to the Warrants, dated April 5, 2023, by and between 180 Life Sciences Corp. and the Selling Stockholder.&nbsp;(filed as Exhibit 10.11 to the registrant&rsquo;s Quarterly Report on Form 10-Q filed on May 15, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023028603/ea176691ex4-2_180lifesci.htm">Form of April Common Warrant (filed as Exhibit 4.2 to the registrant&rsquo;s Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/ea183547ex4-1_180life.htm">Warrant Agent Agreement for Pre-Funded Warrants and Common Warrants, dated August 14, 2023, by and between 180 Life Sciences Corp. and Continental Stock Transfer &amp; Trust Company. (filed as Exhibit 4.1 to the registrant&rsquo;s Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/ea183547ex4-4_180life.htm">Warrant Amendment Agreement, dated August 9, 2023, by and between the Company and Armistice Capital Master Fund Ltd. (filed as Exhibit 4.4 to the registrant&rsquo;s Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023090732/ea189187ex4-1_180life.htm">Form of Warrant Agent Agreement for December 2023 Pre-Funded Warrants and Common Warrants (filed as Exhibit 4.1 to the registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">4.11</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023090732/ea189187ex4-1_180life.htm#a_001">Form of December 2023 Pre-Funded Warrant (included as Annex A to Exhibit 4.11) (filed as Exhibit 4.2 to the registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023090732/ea189187ex4-1_180life.htm#a_002">Form of December 2023 Common Warrant (included as Annex B to Exhibit 4.11) (filed as Exhibit 4.3 to the registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023090732/ea189187ex4-4_180life.htm">Warrant Amendment Agreement, dated November 28, 2023, by and between the Company and the Purchaser (filed as Exhibit 4.4 to the registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.14</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024084859/ea021640301ex4-1_180life.htm">Common Stock Purchase Warrant to purchase 3,000,000 shares of common stock dated September 30, 2024, granted by 180 Life Sciences Corp. to Elray Resources, Inc. (filed as Exhibit 4.1 to the registrant&rsquo;s Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.15</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024088119/ea021778501ex4-1_180life.htm">Form of Warrant to Purchase 1,900,138 Shares of Common Stock Dated October 17, 2024 (filed as Exhibit 4.1 to the registrant&rsquo;s Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>5.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea022078501ex5-1_180life.htm">Opinion of The Loev Law Firm, PC.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390017006223/f8k060717ex10iii_kblmerg.htm">Registration Rights Agreement among the registrant and certain securityholders (filed as Exhibit 10.3 to the registrant&rsquo;s Current Report on Form 8-K filed on June 7, 2017 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390017004247/fs12017ex10viii_kblmerger.htm">Form of Indemnity Agreement (filed as Exhibit 10.8 to the registrant&rsquo;s Registration Statement Form S-1 filed on April 26, 2017 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390019013664/f8k072319ex10-1_kblmerger.htm">Form of Guarantee and Commitment Agreement (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on July 26, 2019 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.4#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020036383/ea129454ex10-3_180lifesci.htm">180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 10.3 to the registrant&rsquo;s Current Report on Form 8-K filed on November 12, 2020 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.5#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021042683/f10q0621ex10-9_180lifesci.htm">Form of Stock Option Agreement (Independent Directors August 2021 Grants)&nbsp;(filed as Exhibit 10.9 to the registrant&rsquo;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021 filed on August 16, 2021 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.6#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021050797/ea148085ex4-2_180lifesci.htm">Form of Stock Option Agreement 180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 4.2 to the registrant&rsquo;s Form S-8 filed on September 30, 2021 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.7#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021050797/ea148085ex4-3_180lifesci.htm">Form of Restricted Stock Grant Agreement and Stock Option Agreement 180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 4.3 to the registrant&rsquo;s Form S-8 filed on September 30, 2021 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390019022944/fs42019ex10-13_kblmerger4.htm">Promissory Note, dated March 15, 2019 issued to KBL IV Sponsor LLC (filed as Exhibit 10.13 to the registrant&rsquo;s Registration Statement Form S-4 filed on November 12, 2019 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020016570/ea123756ex10-2_kblmerg.htm">Registration Rights Agreement, dated June 12, 2020, by and among the Company and the parties signatory thereto (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on July 2, 2020 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020026329/ea126632ex10-2_kblmerger.htm">Registration Rights Agreement, dated September 8, 2020, by and among the Company and the parties signatory thereto (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on September 14, 2020 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.11</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020031987/fs12020ex10-24_kbl4.htm">Amended and Restated Promissory Note, dated September 8, 2020, issued to KBL IV Sponsor LLC (filed as Exhibit 10.24 to the registrant&rsquo;s Registration Statement on Form S-1 filed on October 19, 2020 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390020039561/ea130620ex10-1_180life.htm">Amendment Agreement dated November&nbsp;25, 2020 (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on November&nbsp;27, 2020 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021011376/ea136194ex10-4_180lifesci.htm">Registration Rights Agreement dated as of February&nbsp;23, 2021 by and between 180 Life Sciences Corp. and the purchasers signatory thereto (filed as Exhibit 10.4 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on February&nbsp;24, 2021 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.14#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021013180/ea136864ex10-1_180lifesci.htm">Consultancy Agreement dated February&nbsp;22, 2021, by and between 180 Life Sciences Corp. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on March&nbsp;3, 2021 and incorporated herein by reference)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">10.15#</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021013180/ea136864ex10-5_180lifesci.htm">Ozan Pamir&nbsp;&mdash;&nbsp;Stock Option Agreement effective February&nbsp;26, 2021 (filed as Exhibit&nbsp;10.5 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on March&nbsp;3, 2021 and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.16#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021019967/ea138936ex10-2_180life.htm">First Amendment to Consultancy Agreement dated March&nbsp;31, 2021, by and between 180 Life Sciences Corp. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on April&nbsp;2, 2021 and incorporated herein by reference).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.17</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021044474/ea146220ex10-3_180lifesci.htm">Registration Rights Agreement dated as of August&nbsp;23, 2021 by and between 180 Life Sciences Corp. and the purchasers signatory thereto (filed as Exhibit 10.3 to the registrant&rsquo;s Current Report on Form&nbsp;8-K filed on August&nbsp;24, 2021 and incorporated herein by reference).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.18#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390021060424/ea150938ex10-1_180lifesci.htm">Consulting Agreement dated November 17, 2021, by and between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on November 18, 2021 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.19#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022022364/ea159003ex10-5_180life.htm">First Amendment to Consulting Agreement dated April 27, 2022, between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.5 to the registrant&rsquo;s Current Report on Form 8-K filed on April 28, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.20#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022022364/ea159003ex10-6_180life.htm">Second Amendment to Consulting Agreement dated April 27, 2022, between Cannbiorex Pharma Ltd. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.6 to the registrant&rsquo;s Current Report on Form 8-K filed on April 28, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.21#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022029854/ea160693ex10-4_180life.htm">Second Amendment to Consulting Agreement dated May 26, 2022 and effective as of June 1, 2022, between 180 Life Sciences Corp. and Lawrence Steinman, M.D (filed as Exhibit 10.4 to the registrant&rsquo;s Current Report on Form 8-K filed on May 26, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.22#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022032807/ea161570ex10-1_180life.htm">180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on June 14, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.23&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022040292/ea163025ex10-1_180life.htm">Securities Purchase Agreement dated July 17, 2022, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on July 19, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.24</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023036968/ea177846ex10-43_180lifesci.htm">Warrant Agent Agreement for the July 2022 Common Warrants, dated July 29, 2022, by and between 180 Life Sciences Corp. and Continental Stock Transfer &amp; Trust Company (filed as Exhibit 10.43 to the registrant&rsquo;s Registration Statement on Form S-1 filed on May 5, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.25&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022082245/ea170740ex10-1_180life.htm">Securities Purchase Agreement dated December 20, 2022, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.26</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022082245/ea170740ex10-3_180life.htm">Warrant Agent Agreement for the December 2022 Common Warrants, dated December 22, 2022, by and between 180 Life Sciences Corp. and Continental Stock Transfer &amp; Trust Company (filed as Exhibit 10.3 to the registrant&rsquo;s Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.27#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390022083579/ea170960ex10-1_180lifesci.htm">Third Amendment to Consulting Agreement dated December 28, 2022, between 180 Life Sciences Corp., Cannbiorex Pharma Ltd. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on December 29, 2022 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.28#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023003457/ea171827ex10-1_180lifesci.htm">Amendment to the Warrant Agent Agreement, dated January 13, 2023, by and between 180 Life Sciences Corp. and Continental Stock Transfer &amp; Trust Company (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on January 18, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.29&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023028603/ea176691ex10-1_180lifesci.htm">Securities Purchase Agreement dated April 10, 2023, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.30#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023055659/ea181448ex10-2_180lifesci.htm">First Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on July 10, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.31&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/ea183547ex10-1_180life.htm">Securities Purchase Agreement dated August 9, 2023, by and between 180 Life Sciences Corp. and the Institutional Investor. (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein).</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">10.32#</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023074568/ea184802ex10-2_180life.htm">Form of Stock Option Agreement (First Amended and Restated 2022 Omnibus Incentive Plan) (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on September 7, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.33&pound;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023090732/ea189187ex10-1_180life.htm">Amendment No. 1 to the Securities Purchase Agreement, dated November 28, 2023, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.34#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024003899/ea191699ex10-3_180life.htm">Third Amendment to Consulting Agreement dated January 10, 2024 and effective as of January 1, 2024, between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.3 to the registrant&rsquo;s Current Report on Form 8-K filed on January 17, 2024 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.35#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024018231/ea0200917ex10-1_180life.htm">Offer Letter between 180 Life Science Corp. and Blair Jordan (director) dated February 24, 2024 and effective February 28, 2024 (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on February 29, 2024 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.36#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024021213/ea020144901ex10-1_180life.htm">Offer Letter between 180 Life Science Corp. and Omar Jimenez (director) dated March 4, 2024 and effective March 7, 2024 (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on March 11, 2024 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.37#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024021213/ea020144901ex10-2_180life.htm">Offer Letter between 180 Life Science Corp. and Ryan L. Smith (director) dated March 5, 2024 and effective March 7, 2024&nbsp;(filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on March 11, 2024 and incorporated by reference herein).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.38#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024014908/ea193928ex10-2_180life.htm">Second Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed on February 16, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.39#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1690080/000121390024041030/ea020558901ex10-3_180lifesci.htm">Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Jonathan Rothbard (filed as Exhibit 10.3 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.40#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1690080/000121390024041030/ea020558901ex10-4_180lifesci.htm">Fourth Amendment to Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Lawrence Steinman (filed as Exhibit 10.4 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.41#</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1690080/000121390024041030/ea020558901ex10-5_180lifesci.htm">Executive Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp., Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc.&nbsp;(filed as Exhibit 10.5 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.42</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024076949/ea021386801ex10-1_180life.htm">Separation and Release Agreement dated September 5, 2024 and First Amendment to Separation and Release Agreement dated September 5, 2024, by and between Cannbiorex Pharma Ltd., 180 Life Sciences Corp. and Sir Marc Feldmann (filed as Exhibit 10.1 to the Current Report on Form 8-K filed on September 9, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.43</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024076949/ea021386801ex10-2_180life.htm">Indemnity Agreement dated September 3, 2024 and effective September 5, 2024, between 180 Life Sciences Corp. and Sir Marc Feldmann (filed as Exhibit 10.2 to the Current Report on Form 8-K filed on September 9, 2024, and incorporated herein by reference)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.44</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024088119/ea021778501ex10-1_180life.htm">Form of Warrant Inducement Agreement, by and between the Company and Holder dated October 16, 2024 (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.45</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024088119/ea021778501ex10-2_180life.htm">Financial Advisory Agreement, dated as of October 16, 2024, between A.G.P./Alliance Global Partners and the Company (filed as Exhibit 10.2 to the registrant&rsquo;s Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.46+</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390024091422/ea021884801ex10-1_180life.htm">Offer Letter between 180 Life Science Corp. and Jay Goodman (director) dated October 25, 2024 and effective October 24, 2024 (filed as Exhibit 10.1 to the registrant&rsquo;s Current Report on Form 8-K filed with the Commission on October 29, 2024 and incorporated herein by reference).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1690080/000121390023025521/f10k2022ex21-1_180lifesci.htm">List of Subsidiaries (filed as Exhibit 21.1 to the registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 31, 2023 and incorporated herein by reference).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>23.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea022078501ex23-1_180life.htm">Consent of Marcum LLP, independent registered public accounting firm.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>23.2*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea022078501ex5-1_180life.htm">Consent of&nbsp;The Loev Law Firm, PC&nbsp;(included in Exhibit 5.1).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>24.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_poi">Power of Attorney (included on signature page of this Registration Statement).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>107*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea022078501ex-fee_180life.htm">Filing Fee Table.</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">#</TD><TD STYLE="text-align: justify">Management contract or compensatory plans or arrangements.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&pound;</TD><TD STYLE="text-align: justify">Certain schedules and exhibits have been omitted pursuant
to Item&nbsp;601(a)(5)&nbsp;of Regulation&nbsp;S-K.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1)&nbsp;To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;To include any prospectus
required by Section 10(a)(3)&nbsp;of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof)&nbsp;which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered)&nbsp;and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)&nbsp;if, in the aggregate, the changes
in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;<I><U>Calculation
of Registration Fee</U></I>&rdquo; table in the effective registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&nbsp;To include any
material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided</I>,&nbsp;<I>however</I>, that paragraphs
(a)(1)(i), (a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section
15(d)&nbsp;of the Securities Exchange Act that are incorporated by reference in the registration statement, or is contained in a form
of prospectus filed pursuant to Rule 424(b)&nbsp;that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2)&nbsp;That, for the purpose
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3)&nbsp;To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) That, for the purpose
of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b)&nbsp;as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance
on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.&nbsp;<I>Provided</I>,&nbsp;<I>however</I>,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) The undersigned registrant
hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding)&nbsp;is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Palo Alto, State of California, on November 15,&nbsp;2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>180 LIFE SCIENCES CORP.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><I>/s/ Blair Jordan</I></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: top">Blair Jordan</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD STYLE="vertical-align: top">Interim Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_poi"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE
PRESENTS, that the persons whose signature appears below constitute and appoint Blair Jordan and Omar Jimenez, and each of them, as true
and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any
registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933),
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such
things in their names and behalf in their capacities as officers and directors to enable 180 Life Sciences Corp. to comply with the provisions
of the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully
to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%; text-align: center"><B>Signature</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 43%; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><B>Date</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><I>/s/ Blair Jordan</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Interim Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 15, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Blair Jordan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><I>/s/ Omar Jimenez</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Financial Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 15, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Omar Jimenez</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Principal Financial and Accounting Officer)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><I>/s/ Lawrence Steinman</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 15, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Lawrence Steinman</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><I>/s/ Ryan Smith</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 15, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Ryan Smith</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><I>/s/ Jay Goodman</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November&nbsp;&nbsp;15, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Jay Goodman</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>











































































































</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "ea0220785-s1_180life.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 317599}]
{"company-data": {"conformed-name": "180 Life Sciences Corp.", "cik": "0001690080", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "813832378", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-283265", "film-number": "241468084"}, "business-address": {"street1": "3000 EL CAMINO REAL", "street2": "BLDG 4, STE 200", "city": "PALO ALTO", "state": "CA", "zip": "94306", "phone": "650-507-0669"}, "mail-address": {"street1": "3000 EL CAMINO REAL", "street2": "BLDG 4, STE 200", "city": "PALO ALTO", "state": "CA", "zip": "94306"}, "former-company": {"former-conformed-name": "KBL MERGER CORP. IV", "date-changed": "20161115"}}
As filed with the U.S. Securities and Exchange Commission on November 15, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
180 Life Sciences Corp.
(Exact name of registrant as specified in its
charter)
Delaware
2834
90-1890354
(State or other jurisdiction of
(Primary Standard Industrial
(I.R.S. Employer
incorporation or organization)
Classification Code Number)
Identification Number)
3000 El Camino Real, Bldg. 4, Suite 200
Palo Alto, CA 94306
(650) 507-0669
(Address, including zip code, and telephone
number, including area code, of registrant's principal executive offices)
Mr. Blair Jordan
Chief Executive Officer
180 Life Sciences Corp.
3000 El Camino Real, Bldg. 4, Suite 200
Palo Alto, CA 94306
(650) 507-0669
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
David M. Loev, Esq.
John S. Gillies, Esq.
The Loev Law Firm, PC
6300 West Loop South, Suite 280
Bellaire, Texas 77401
Telephone: (713) 524-4110
Approximate date of commencement
of proposed sale to the public:
From time to time after this registration statement becomes effective.
If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box:
☒
If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.
☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.
☐
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of "
large accelerated filer,
" "
accelerated filer,
" "
smaller
reporting company,
" and "
emerging growth company
" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.
The information contained
in this prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION,
DATED NOVEMBER 15, 2024
PRELIMINARY PROSPECTUS
1,900,138 Shares of Common Stock
This prospectus relates solely
to the offer and sale from time to time of up to an aggregate of 1,900,138 shares of our common stock, par value $0.0001 per share, of
180 Life Sciences Corp., a Delaware corporation (the "
Company,
" "
we,
" "
our
" or
"
us
"), by the selling stockholder identified in this prospectus (the "
Selling Stockholder
"). The
shares of common stock being registered for resale hereunder consist of: 1,900,138 shares of common stock issuable upon the exercise of
the October 2024 Warrants (as defined herein), acquired by the Selling Stockholder, pursuant to an Inducement Agreement (as defined herein)
entered into between us and the Selling Stockholder (the "
Warrants,
" and all of the shares of common stock issuable
upon exercise of the Warrants, the "
Shares
").
Each of the Warrants are exercisable
at an exercise price of $1.50. We are not selling any common stock under this prospectus and will not receive any of the proceeds from
the sale of the Shares by the Selling Stockholder. However, if all of the Warrants that are covered by this prospectus are exercised for
cash, we may receive proceeds of up to approximately $2,850,207. We intend to use those proceeds, if any, for operationalizing and developing
our recently acquired Technology Gaming Platform, and general corporate and legal expenses. We will bear all other costs, expenses and
fees in connection with the registration of the Shares. The Selling Stockholder will bear all commissions and discounts, if any, attributable
to the sales of Shares.
The Selling Stockholder may
offer such Shares from time to time as it may determine through public or private transactions or through other means described in the
section entitled "
Plan of Distribution
" beginning on page 18 of this prospectus, at prevailing market prices,
at prices related to prevailing market prices or at privately negotiated prices. This prospectus does not necessarily mean that the Selling
Stockholder will offer or sell the Shares. We cannot predict when or in what amounts the Selling Stockholder may sell any of the Shares
offered by this prospectus. Any Shares subject to resale hereunder will have been issued by us and acquired by the Selling Stockholder
prior to any resale of such Shares pursuant to this prospectus. Because all of the Shares offered under this prospectus are being offered
by the Selling Stockholder, we cannot currently determine the price or prices at which the Shares may be sold under this prospectus.
Our common stock is traded
on the Nasdaq Capital Market ("
Nasdaq
") under the symbol "
ATNF
". On November 14, 2024, the
last reported sale price for our common stock as reported on Nasdaq was $2.68 per share.
INVESTING IN OUR SECURITIES
INVOLVES SUBSTANTIAL RISKS. SEE THE SECTION TITLED "
RISK FACTORS
" BEGINNING ON PAGE 7 OF THIS PROSPECTUS TO READ
ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING OUR SECURITIES.
NEITHER THE SECURITIES
AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY
OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus is              , 2024.
TABLE OF CONTENTS
About This Prospectus
iii
Prospectus Summary
1
Risk Factors
7
Incorporation by Reference
11
Cautionary Note Regarding Forward-Looking Statements
12
Use of Proceeds
14
Dividend Policy
15
Beneficial Ownership of Securities
16
Selling Stockholder
17
Plan of Distribution
18
Description of Capital Stock
20
Legal Matters
24
Experts
24
Where You Can Find More Information
24
i
Our logo and some of our trademarks
and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property
of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®,
™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will
not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective
owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.
The market data and certain
other statistical information used throughout this prospectus are based on independent industry publications, reports by market research
firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey
data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness
of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications
and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are
not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as
they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various
factors, including those discussed under the section entitled "
Risk Factors
" of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included
herein, as well as the data of competitors as they relate to 180 Life Sciences Corp., is also based on our good faith estimates.
Unless the context requires
otherwise, references to the "
Company,
" "
we,
" "
us,
" "
our,
"
"
180 Life
", "
180LS
" and "
180 Life Sciences Corp.
" refer specifically to 180 Life
Sciences Corp. and its consolidated subsidiaries. References to "
KBL
" refer to the Company prior to the November 6,
2020 Business Combination.
In addition, unless the context
otherwise requires and for the purposes of this prospectus only:
●
"
CAD
" refers to Canadian dollars;
●
"
Exchange Act
" refers to the Securities
Exchange Act of 1934, as amended;
●
"
£
" or "
GBP
" refers
to British pounds sterling;
●
"
SEC
" or the "
Commission
"
refers to the United States Securities and Exchange Commission; and
●
"
Securities Act
" refers to the Securities
Act of 1933, as amended.
Effective on December 19,
2022 at 12:01 a.m. Eastern Time, we affected a 1-for-20 reverse stock split of our then outstanding common stock, with any fractional
shares rounded up to the nearest whole share. Effective on February 28, 2024 at 12:01 a.m. Eastern Time, we affected a 1-for 19 reverse
stock split of our then outstanding common stock with any fractional shares rounded up to the nearest whole share.
In connection with the reverse
splits, all outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common
stock were adjusted, as required by the terms of each security. The number of shares available to be awarded under the Company's
equity incentive plans were also appropriately adjusted. Following the reverse splits, the par value of the common stock remained unchanged
at $0.0001 par value per share. The reverse splits did not change the authorized number of shares of common stock or preferred stock.
The effects of the reverse
stock splits have been retroactively reflected throughout this prospectus.
ii
About This Prospectus
This prospectus is part of
a registration statement on Form S-1 that we filed with the SEC. Under this registration statement, the Selling Stockholder may, from
time to time, sell the shares of common stock offered by it as described in this prospectus. We will not receive any proceeds from the
sale by such Selling Stockholder of the Shares offered by it as described in this prospectus. We will not receive any proceeds from the
sale of Shares pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash,
if any.
Neither we nor the Selling
Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this
prospectus or any applicable prospectus supplement or any free writing prospectus prepared by or on behalf of us or to which we have referred
you. Neither we nor the Selling Stockholder take responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. Neither we nor the Selling Stockholder will make an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any
date other than the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed since
that date.
We may also provide a prospectus
supplement or post-effective amendment to the registration statement to add information to, or update or change information contained
in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the
registration statement together with the additional information to which we refer you in the sections of this prospectus entitled "
Incorporation
by Incorporation
" and "
Where You Can Find More Information.
"
iii
Prospectus Summary
The following summary highlights
selected information contained elsewhere in this prospectus and/or incorporated by reference herein, and does not contain all of the information
that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire
prospectus and the information incorporated by reference herein.
Our Company
We were formed as a clinical
stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis
by employing innovative research, and, where appropriate, combination therapy. In September 2024, we completed the acquisition of certain
source code and intellectual property relating to an online blockchain casino, and moving forward, we plan to focus the majority of our
operations on the creation of the online blockchain casino, while still working to complete the development of certain prior therapeutics
for unmet medical needs.
Biotechnology Product Development
We have three product development
platforms:
●
fibrosis and anti-tumor necrosis factor ("
TNF
");
●
drugs which are derivatives of cannabidiol ("
CBD
") or cannabigerol ("
CBG
") analogues ("
SCAs
"); and
●
alpha 7 nicotinic acetylcholine receptor ("
α7nAChR
").
Due
to restrictions in the Company's resources, the Company has slowed down research and development activities significantly in the
SCA platform and the anti-TNF platform, and the Company has not made progress in the α7nAChR platform and has suspended further
research and development activity in this program in the meantime.
The
Company is currently evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to
maximize value for its stockholders. Potential strategic alternatives that may be explored or evaluated by the Company as part of this
process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sale of assets, licensing
or other strategic transactions involving the Company.
Planned iGaming Casino
Operations
On September 29, 2024, we
entered into an Asset Purchase Agreement (the "
Purchase Agreement
") with Elray Resources, Inc. ("
Elray
").
Pursuant to the Purchase Agreement, Elray agreed to sell us certain source code and intellectual property relating to an online blockchain
casino (the "
Purchased Assets
") in consideration for 1,000,000 shares of newly designated Series B Convertible
Preferred Stock (the "
Preferred Stock
", and the shares of common stock issuable upon conversion thereof, the "
Conversion
Shares
") and warrants to purchase 3,000,000 shares of common stock of the Company (the "
Purchase Warrants
"
and the shares of common stock issuable upon exercise thereof, the "
Purchase Warrant Shares
"). The acquisition of the
Purchased Assets was completed on September 30, 2024.
We are planning to strategically
enter into the online gaming industry, utilizing the Purchased Assets, i.e., our newly acquired "
back-end
" gaming platform,
which incorporates blockchain technology and full cryptocurrency operability (the "
Gaming Technology Platform
"). The
Company plans to use this technology platform to establish a blockchain-based business aimed at the global iGaming market. Initially focusing
on B2C (business-to-consumer) online casinos, the Company also plans to expand into a B2B (business-to-business) model, offering a seamless
blockchain-enabled technology platform for gaming operators worldwide. In addition, management has identified certain global iGaming industry
characteristics and trends that they believe make potential acquisition opportunities attractive. Management believes that the combination
of the Gaming Technology Platform and the strength of a Nasdaq listing make the Company an attractive consolidation vehicle for the iGaming
industry, and plan to work to identify potential acquisitions (although no targets exist at present).
1
Warrants and Related Transactions
August 2023 Offering
On August 9, 2023, the Company
entered into a Securities Purchase Agreement (the "
August SPA
") with the Selling Stockholder, an accredited investor
(the "
Purchaser
"), in addition to certain purchasers, pursuant to which the Company agreed to sell an aggregate of
35,102 shares of common stock (the "
August 2023 Shares
"), pre-funded warrants to purchase up to an aggregate of 207,814
shares of common stock ("
August 2023 Pre-Funded Warrants
"), and common stock warrants to purchase up to an aggregate
of 242,915 shares of common stock (the "
August 2023 Common Warrants
"), at a combined purchase price of $12.35 per share
and warrant (the "
August 2023 Offering
"). Aggregate gross proceeds from the August 2023 Offering were $2,999,606. Net
proceeds to the Company from the offering, after deducting the placement agent fees and other offering expenses payable by the Company,
were approximately $2.7 million. The placement agent fees and offering expenses of approximately $300,000 were accounted for as a reduction
of additional paid in capital. The August 2023 Offering closed on August 14, 2023.
Amendment to August 2023 Offering
On October 11, 2023, the Company
received a letter from Listing Qualifications Department of The Nasdaq Stock Market LLC ("
Nasdaq
"), stating that Nasdaq
had determined that the Company failed to comply with Nasdaq's shareholder approval requirements set forth in Listing Rule 5635(d),
which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the
pre-transaction shares outstanding at less than the Minimum Price. The letter from Nasdaq referred to the August 2023 Offering and requested
the Company to submit a plan of compliance no later than November 27, 2023. On November 9, 2023, the Company submitted a plan of compliance
to Nasdaq, and on November 14, 2023, Nasdaq provided a letter of extension to the Company.
Pursuant to the compliance
plan submitted to Nasdaq, on November 28, 2023, the Company entered into an amendment to the August 2023 Offering ("
Amendment
to the August 2023 Offering
"), whereby (i) the Purchaser agreed to pay an additional $830,769 in connection with the repricing
of the August 2023 Shares and August 2023 Pre-Funded Warrants (the "
Repricing Amount
"), (ii) the Company agreed to
issue to the Purchaser additional pre-funded warrants to purchase up to 257,205 shares of common stock, with an exercise price of $0.0019
per share (the "
Additional Pre- Funded Warrants
"), and warrants to purchase up to 477,058 shares of common stock, with
an exercise price of $3.23 per share (the "
Additional Common Warrants
", and collectively with the Additional Pre-Funded
Warrants, the "
Additional Warrants
"), and (iii) the Company and the Purchaser agreed to enter into a warrant amendment
agreement (as described below). Net proceeds to the Company from the repricing, after deducting the placement agent fees and other offering
expenses payable by the Company, were approximately $0.8 million. The placement agent fees and offering expenses of approximately $60,000
were accounted for as a reduction of additional paid in capital. The Amendment to the August 2023 Offering closed on December 1, 2023.
In accordance with the Amendment
to the August 2023 Offering, the Company entered into a warrant amendment agreement to amend the following outstanding warrants held by
the Purchaser: (i) warrants to purchase up to 16,138 shares of common stock issued in July 2022; (ii) warrants to purchase up to
135,339 shares of common stock issued in December 2022; (iii) warrants to purchase up to 82,668 shares of common stock issued in April
2023; and (iv) warrants to purchase up to 242,915 shares of common stock issued in August 2023 (collectively, the "
Existing Common
Warrants
"). Pursuant to the warrant amendment agreement, the Existing Common Warrants were amended to have an exercise price
of $3.23 per share, and to expire on the fifth anniversary of the date that the stockholders of the Company approved the issuance of shares
of common stock upon exercise of such Existing Common Warrants, which stockholder approval date, which was February 16, 2024.
2
Inducement Agreement
On
October 16, 2024, we entered into a warrant inducement agreement (the "
Inducement Agreement
") with Armistice Capital
Master Fund Ltd. (the "
Holder
") of 477,058 Additional Common Warrants and 473,011 of the Existing Common Warrants (collectively,
the "
Exercised Warrants
"), pursuant to which the Holder agreed to exercise for cash the Exercised Warrants to purchase
950,069 shares of common stock at an exercise price of $3.48 per share ($0.25 greater than the $3.23 per share exercise price of such
Exercised Warrants). On
October 16 and 17, 2024, the Exercised Warrants were exercised in full for cash by the Holder and the Company received $3,306,240 before
deducting financial advisory fees and other expenses payable by us.
In
consideration of the Holder's agreement to exercise the Exercised Warrants in accordance with the Inducement Agreement, the Company
agreed to issue new unregistered Warrants to Purchase Shares of Common Stock (the "
October 2024 Warrants
") to purchase
a number of shares of common stock equal to 200% of the number of shares of common stock issued upon exercise of the Exercised Warrants,
i.e., warrants to purchase up to 1,900,138 shares of common stock (the "
October 2024 Warrant Shares
"). The October
2024 Warrants were immediately exercisable and have a term of exercise of five years.
The
Company agreed in the Inducement Agreement to file a registration statement on Form S-1 to register the resale of the New Warrant Shares
upon exercise of the October 2024 Warrants (the "
Resale Registration Statement
") by November 15, 2024, and to use commercially
reasonable efforts to have such Resale Registration Statement declared effective by the Commission within sixty (60) calendar days following
the date of filing with the Commission (or ninety (90) calendar days following the date of filing with the Commission in the event of
a 'full review' by the Commission) and to keep the Resale Registration Statement effective at all times until no holder of
the October 2024 Warrants owns any October 2024 Warrants or October 2024 Warrant Shares. In the event that the Company fails to timely
deliver to the Holder the October 2024 Warrant Shares without restrictive legends, the Company has agreed to pay certain liquidated damages
to the Holder. The registration statement of which this prospectus forms a part is the required Resale Registration Statement, which was
timely filed.
The
Company has used, and plans to continue to use, the net proceeds from these transactions to advance the commercialization of the
Purchased Assets recently acquired by the Company, and for working capital, and other general corporate purposes.
The
October 2024 Warrants have an exercise price of $1.50 per share. The exercise price and the number of shares of common stock issuable
upon exercise of each October 2024 Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances,
upon a fundamental transaction, a holder of October 2024 Warrants will be entitled to receive, upon exercise of the October 2024 Warrants,
the kind and amount of securities, cash or other property that such holder would have received had they exercised the October 2024 Warrants
immediately prior to the fundamental transaction.
The
Company may not affect the exercise of October 2024 Warrants, and the applicable Holder will not be entitled to exercise any portion of
any such October 2024 Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock
beneficially owned by the holder of such October 2024 Warrant (together with its affiliates) to exceed 4.99% or 9.99%, as applicable,
of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of such October 2024 Warrants.
The
Company engaged A.G.P./Alliance Global Partners ("
A.G.P.
") to provide exclusive financial services in connection with
the transactions summarized above and, pursuant to a Financial Advisory Agreement between the Company and A.G.P., paid A.G.P. a financial
advisory fee of $232,000, and an alternative transaction fee of $100,000. In addition, we reimbursed A.G.P. for its accountable legal
expenses in connection with the exercise of the Exercised Warrants and the issuance of the October 2024 Warrants of $65,000 and $10,000
of non-accountable expenses. In addition, we paid A.G.P. $29,923, half of the financial advisory fees due in connection with advisory
fees in 2023 and agreed to pay $29,923 for advisory fees in the future. As of October 31, 2024, a total of $436,923 related to the aforementioned
transaction has been paid to A.G.P in addition to the $29,923 of advisory fee, and there is a balance outstanding of $29,923 for the aforementioned
advisory fees.
3
Corporate Information
We were originally formed
as KBL Merger Corp. IV, a blank check company organized under the laws of the State of Delaware on September 7, 2016, which consummated
its initial public offering on June 7, 2017. On November 6, 2020, we consummated a business combination and, in connection therewith,
changed our name to 180 Life Sciences Corp.
Our principal executive offices
are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, and our telephone number is (650) 507-0669. We
maintain a website at www.180lifesciences.com. We have not incorporated by reference into this prospectus the information in, or that
can be accessed through, our website, and you should not consider it to be a part of this prospectus.
The Offering
Shares offered by the Selling Stockholder:
We are registering the resale by the Selling Stockholder named in this prospectus, or their permitted transferees, of an aggregate of up to an aggregate of 1,900,138 Shares by the Selling Stockholder identified in this prospectus. The Shares being registered for resale hereunder consist of the shares of common stock issuable upon exercise of the October 2024 Warrants.
Common stock outstanding prior to this offering:
1,976,999 shares of common stock as of November 15, 2024.
Use of proceeds:
The Selling Stockholder will receive the proceeds from the sale of the Shares offered hereby. We will not receive any proceeds from the sale of the Shares. However, if all of the Warrants that are covered by this prospectus are exercised for cash, we may receive proceeds of up to approximately $2,850,207.
Risk Factors:
The purchase of our securities involves a high degree of risk. See "
Risk Factors
" beginning on page 7 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities.
Nasdaq Symbol:
Our common stock is listed on Nasdaq under the symbol "
ATNF
".
The number of shares of our
common stock outstanding is based on 1,900,138 shares outstanding as of November 15, 2024, and excludes, as of such date:
●
22,956 shares of common stock issuable upon the exercise of
outstanding stock options;
●
6,397 additional shares of our common stock reserved for future
issuance under our 2020 Omnibus Incentive Plan;
●
16,052 additional shares of our common stock reserved for
future issuance under our 2022 Omnibus Incentive Plan;
●
(a) 15,132 shares of common stock issuable upon the exercise
of outstanding public warrants exercisable at an exercise price of $4,370.00 per share, (b) 6,748 shares of common stock issuable upon
the exercise of certain outstanding private placement warrants at an exercise price of $1,900.00 per share, (d) 6,579 shares of common
stock issuable upon the exercise of certain outstanding private placement warrants at an exercise price of $2,850.00 per share, (e) 4,049
shares of common stock issuable upon exercise of certain outstanding warrants to purchase shares of common stock with an exercise price
of $3.23 per share, (f) 3,000,000 shares of common stock issuable upon the exercise of warrants to purchase 3,000,000 shares of common
stock with an exercise price of $1.68 per share, (g) 168 shares of common stock issuable upon exercise of warrants which expire on May
2, 2025, and (h) 1,900,138 shares of common stock issuable upon exercise of the October 2024 Warrants, with an exercise price of $1.50
per share; and
●
up to a maximum of 10,000,000 shares of common stock issuable
upon conversion of 1,000,000 shares of Series B Convertible Preferred Stock.
4
Summary Risk Factors
We face risks and uncertainties
related to our business, many of which are beyond our control. In particular, risks associated with our business include:
●
Our need for additional financing, both near term and long
term, to support our operations, our ability to raise such financing as needed, the terms of such financing, if available, potential
significant dilution associated therewith, and covenants and restrictions we may need to comply with in connection with such funding.
●
Our ability to create or purchase a front end for our back
end blockchain casino intellectual property assets, commercialize our planned blockchain casino, obtain required licenses and customers,
and ultimately generate revenues through such operations.
●
The fact that we are currently an iGaming/clinical stage biotechnology
company that had no revenue for the three or nine months ended September 30, 2024, and for the years ended December 31, 2023 and 2022,
and may not generate significant revenue for the near term.
●
Our dependence on the success of our future product candidates,
some of which may not receive regulatory approval or be successfully commercialized; problems in our manufacturing process for our new
products and/or our failure to comply with manufacturing regulations, or unexpected increases in our manufacturing costs; problems with
distribution of our products; and failure to adequately market our products.
●
The fact that our accounts payable are significant, and we
do not currently have sufficient funds to pay such accounts payable, a large portion of which are past due.
●
Risks from intense competition from companies with greater
resources and experience than we have.
●
Our ability to receive regulatory approvals for our product
candidates, and the timeline and costs associated therewith, including the uncertainties associated with the clinical development and
regulatory approval of our drug candidates, including potential delays in the enrollment and completion of clinical trials, issues raised
by the U.S. The Food and Drug Administration (FDA) and The Medicines and Healthcare products Regulatory Agency (MHRA).
●
Risks that our future product candidates, if approved by regulatory
authorities, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from new
products.
●
The fact that the majority of our license agreements provide
the licensors and/or counter-parties the right to use, own and/or exploit such licensed intellectual property.
5
●
Liability from lawsuits (including product liability lawsuits,
stockholder lawsuits and regulatory matters), including judgments, damages, fines and penalties and including the outcome of currently
pending litigation, potential future government investigations, and other proceedings that may adversely affect our business and results
of operations.
●
Our ability to comply with existing and future rules and regulations.
●
Our ability to adequately protect our proprietary technology
and intellectual property, claims and liability from third parties regarding our alleged infringement of their intellectual property.
●
The effect of current and future regulation, the Company's
ability to comply with regulations (both current and future) and potential penalties in the event it fails to comply with such regulations
and changes in the enforcement and interpretation of existing laws and regulations and the adoption of new laws and regulations that
may unfavorably impact our business.
●
Failure of our information technology systems, including cybersecurity
attacks or other data security incidents, that could significantly disrupt the operation of our business.
●
The liquidation preference associated with, dilution caused
by the conversion of, and voting rights associated with, our Series B Convertible Preferred Stock.
●
The fact that we may acquire other companies which could divert
our management's attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our
operating results and if we make any acquisitions, they may disrupt or have a negative impact on our business.
●
The effect of changes in inflation and interest rates, and
economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts
of war (including the ongoing Ukraine/Russian and Hamas/Israel conflict) and other large-scale crises, as well as the potential
implications of a Congressional impasse over the U.S. debt limit or possible future U.S. governmental shutdowns over budget disagreements.
●
Our ability to maintain our listing of our common stock and
public warrants on the Nasdaq Capital Market, including our current non-compliance with Nasdaq's continued listing rules due to
our failure to maintain a majority of independent directors and an audit committee of at least three independent directors.
●
The reliance on suppliers of third-party gaming content and
the cost of such content.
●
The ability of the Company to obtain gaming licenses.
●
The Company's reliance on its management.
●
The ability of the Company to compete in the iGaming market.
●
The ability to compete against existing and new competitors.
●
The ability to manage expenses associated with sales and
marketing and necessary general and administrative and technology investments.
●
General consumer sentiment and economic conditions that may
affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic
slowdowns.
●
other risks and uncertainties, including those described
under, and incorporated by reference into, "
Risk Factors
", below.
6
Risk Factors
Investing in shares of our
common stock involves a high degree of risk. Before making an investment decision, you should carefully consider and evaluate the risks
described in the "
Risk Factors
" section in our most recent Annual Report on Form 10-K, as well as any updates to those
risk factors in our subsequent Quarterly Reports on Form 10-Q, and below, together with all of the other information appearing in or incorporated
by reference into this prospectus, before deciding whether to purchase any of the common stock being offered. The risks described in these
documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic,
business, competitive, regulatory or other factors that could have material adverse effects on our future results. Our business, financial
condition or results of operations could be materially adversely affected by any of these risks. The trading price of shares of our common
stock could decline due to any of these risks, and you may lose all or part of your investment. Please also read carefully the section
entitled "
Cautionary Note Regarding Forward-Looking Statements
.
"
Sales of substantial
amounts of our common stock by the selling stockholder, or the perception that these sales could occur, could adversely affect the
price of our common stock.
The sale by the selling stockholder
of a significant number of shares of common stock could have a material adverse effect on the market price of our common stock. In addition,
the perception in the public markets that the selling stockholder may sell all or a portion of its shares as a result of the
registration of such shares for resale pursuant to this prospectus could also in and of itself have a material adverse effect
on the market price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the
availability of those shares of common stock for sale will have on the market price of our common stock.
We currently have
an illiquid and volatile market for our common stock, and the market for our common stock is and may remain illiquid and volatile in the
future.
We currently have a highly
sporadic, illiquid and volatile market for our common stock, which market is anticipated to remain sporadic, illiquid and volatile in
the future. During the last 52 weeks our common stock has traded as high as $17.75 per share and as low as $1.16 per share. The market
price of our common stock may continue to be highly volatile and subject to wide fluctuations. Our financial performance, government regulatory
action, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our common
stock.
●
"
short squeezes
";
●
comments by securities analysts or other third parties, including
blogs, articles, message boards and social and other media;
●
large stockholders exiting their position in our securities
or an increase or decrease in the short interest in our securities;
●
actual or anticipated fluctuations in our financial and operating
results;
●
changes in foreign currency exchange rates;
●
the commencement, enrollment or results of our planned or
future clinical trials of our product candidates or those of our competitors;
●
the success of competitive drugs or therapies;
●
regulatory or legal developments in the U.S. and other countries;
●
the success of competitive products or technologies;
●
developments or disputes concerning patent applications,
issued patents or other proprietary rights;
●
the recruitment or departure of key personnel;
7
●
the level of expenses related to our iGaming operations,
product candidates or clinical development programs;
●
litigation matters, including amounts which may or may not
be recoverable pursuant to our officer and director insurance policies, regulatory actions affecting the Company and the outcome thereof;
●
the results of our efforts to discover, develop, acquire
or in-license additional product candidates;
●
actual or anticipated changes in estimates as to financial
results, development timelines or recommendations by securities analysts;
●
our inability to obtain or delays in obtaining adequate drug
supply for any approved drug or inability to do so at acceptable prices;
●
disputes or other developments relating to proprietary rights,
including patents, litigation matters and our ability to obtain patent protection for our technologies;
●
the timing and outcome of our plans to commercialize our
iGaming intellectual property;
●
significant lawsuits, including patent or stockholder litigation;
●
variations in our financial results or those of companies
that are perceived to be similar to us;
●
changes in the structure of healthcare payment systems, including
coverage and adequate reimbursement for any approved drug;
●
market conditions in the pharmaceutical and biotechnology
sectors;
●
general economic, political, and market conditions and overall
fluctuations in the financial markets in the U.S. and abroad; and
●
investors' general perception of us and our business.
Our common stock is listed
on the Nasdaq Capital Market under the symbol "
ATNF
.
" Our stock
price may be impacted by factors that are unrelated or disproportionate to our operating performance. The stock markets in general have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market
fluctuations may adversely affect the trading price of our common stock. Additionally, general economic, political and market conditions,
such as recessions, inflation, war, interest rates or international currency fluctuations may adversely affect the market price of our
common stock. Due to the limited volume of our shares which trade, we believe that our stock prices (bid, ask and closing prices) may
not be related to our actual value, and not reflect the actual value of our common stock. You should exercise caution before making an
investment in us.
Stock markets in general and
our stock price in particular have recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of those companies and our company. For example, during 2022, the closing sales prices of our common stock
ranged from a post-split adjusted high of $1,482.04 per share to a low of $23.56 per share, during fiscal 2023, the closing sales prices
of our common stock ranged from a high of $100.70 per share to a low of $3.21 per share and during fiscal 2024 (through the date of this
prospectus), the closing sales prices of our common stock ranged from a post-split adjusted high of $6.47 per share to a low of $1.18
per share. During this time, we do not believe that we have experienced any material changes in our financial condition or results of
operations that would explain such price volatility or trading volume; however, we have sold equity which was dilutive to existing stockholders.
These broad market fluctuations may adversely affect the trading price of our securities. Additionally, these and other external factors
have caused and may continue to cause the market price and demand for our common stock to fluctuate substantially, which may limit or
prevent our stockholders from readily selling their shares of our common stock and may otherwise negatively affect the liquidity of our
common stock.
8
Additionally, as a result
of the illiquidity of our common stock, investors may not be interested in owning our common stock because of the inability to acquire
or sell a substantial block of our common stock at one time. Such illiquidity could have an adverse effect on the market price of our
common stock. In addition, a shareholder may not be able to borrow funds using our common stock as collateral because lenders may be unwilling
to accept the pledge of securities having such a limited market. An active trading market for our common stock may not develop or, if
one develops, may not be sustained.
In the past, many companies
that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be
the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our
management's attention from other business concerns, which could seriously harm our business.
The exercise of the
outstanding options and warrants, and the sale of common stock upon exercise thereof, may adversely affect the trading price of our securities.
As of the date of this prospectus,
we had 22,891 shares of common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price of
$61.92 per share; (a) 15,132 shares of common stock issuable upon the exercise of outstanding public warrants exercisable at an exercise
price of $4,370.00 per share, (b) 6,748 shares of common stock issuable upon the exercise of certain outstanding private placement
warrants at an exercise price of $1,900.00 per share, (d) 6,579 shares of common stock issuable upon the exercise of certain outstanding
private placement warrants at an exercise price of $2,850.00 per share, (e) 4,049 shares of common stock issuable upon exercise of certain
outstanding warrants to purchase shares of common stock with an exercise price of $3.23 per share, (f) 3,000,000 shares of common
stock issuable upon the exercise of warrants to purchase 3,000,000 shares of common stock with an exercise price of $1.68 per share, (g)
168 shares of common stock issuable upon exercise of warrants which expire on May 2, 2025, and (h) 1,900,138 shares of common stock issuable
upon exercise of the October 2024 Warrants with an exercise price of $1.50 per share. For the life of the options and warrants, the holders
have the opportunity to profit from a rise in the market price of our common stock without assuming the risk of ownership. The issuance
of shares upon the exercise of outstanding securities will also dilute the ownership interests of our existing stockholders.
The availability of these
shares for public resale, as well as any actual resales of these shares, could adversely affect the trading price of our common stock.
We cannot predict the size of future issuances of our common stock pursuant to the exercise of outstanding options or warrants or conversion
of other securities, or the effect, if any, that future issuances and sales of shares of our common stock may have on the market price
of our common stock. Sales or distributions of substantial amounts of our common stock (including shares issued in connection with an
acquisition), or the perception that such sales could occur, may cause the market price of our common stock to decline.
In addition, the common stock
issuable upon exercise/conversion of outstanding convertible securities may represent overhang that may also adversely affect the market
price of our common stock. Overhang occurs when there is a greater supply of a company's stock in the market than there is demand
for that stock. When this happens the price of our stock will decrease, and any additional shares which stockholders attempt to sell in
the market will only further decrease the share price. If the share volume of our common stock cannot absorb shares sold by holders of
our outstanding convertible securities, then the value of our common stock will likely decrease.
9
There may not be sufficient
liquidity in the market for our securities in order for investors to sell their shares. The market price of our common stock may continue
to be volatile.
The market price of our common
stock will likely continue to be highly volatile. Some of the factors that may materially affect the market price of our common stock
are beyond our control, such as conditions or trends in the industry in which we operate or sales of our common stock. This situation
is attributable to a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts,
stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if
we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours
or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable.
As a consequence, there may
be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a mature issuer which
has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price.
It is possible that a broader or more active public trading market for our common stock will not develop or be sustained, or that trading
levels will not continue. These factors may materially adversely affect the market price of our common stock, regardless of our performance.
In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly
affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific
companies. These broad market fluctuations may adversely affect the market price of our common stock.
Stockholders may be
diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares of our
common stock.
Wherever possible, our Board
will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will
consist of restricted shares of our common stock or where shares are to be issued to our officers, directors and applicable consultants.
Our Board of Directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules and regulations (which generally
require stockholder approval for any transactions which would result in the issuance of more than 20% of our then outstanding shares of
common stock or voting rights representing over 20% of our then outstanding shares of stock, subject to certain exceptions), to issue
all or part of the authorized but unissued shares of common stock. In addition, we may attempt to raise capital by selling shares of our
common stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders,
which may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing
management's ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting
existing management.
10
Incorporation by
Reference
The SEC allows us to "
incorporate
by reference
" into this prospectus the information in other documents that we file with it. This means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be a part
of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information contained
in documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference in this prospectus the documents
listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior
to the termination of the offering under this prospectus; provided, however, that we are not incorporating, in each case, any documents
or information deemed to have been furnished and not filed in accordance with SEC rules:
(a)
The Company's Annual Report on
Form 10-K
for the year ended December 31, 2023, filed with
    the SEC on March 25, 2024, as amended by
Amendment No. 1
thereto filed with the SEC on April 29, 2024 (File No. 001-38105) (as
    amended, the "
Annual Report
");
(b)
The Company's Quarterly Report on
Form 10-Q
for the quarter ended March 31, 2024, filed with the SEC on May 15, 2024 (File No. 001-38105), the Company's Quarterly Report on
Form 10-Q
for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024 and the Company's Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024 (File No. 001-38105);
(c)
The Company's Definitive Proxy Statement on
Schedule 14A
, filed with the Commission on November 12, 2024, to the extent filed and not furnished with the Commission;
(c)
The Company's Current Reports on Form 8-K (other than information furnished rather than filed)
    filed with the SEC on
January
    16, 2024
,
January 17,
    2024
,
January 29, 2024
,
February
    16, 2024
,
February 20,
    2024
,
February 26,
    2024
,
February 28,
    2024
,
February 29,
    2024
,
March 1, 2024
,
March 8, 2024
,
March 11, 2024
,
March 14, 2024
,
April 19, 2024
,
May 9, 2024
,
May 15, 2024
,
May 21, 2024
,
July 2, 2024
,
July 23, 2024
,
July 30, 2024
,
September 9, 2024
,
September 12, 2024
,
October 3, 2024
,
October 9, 2024
,
October 16, 2024
,
October 16, 2024
,
October 21, 2024
,
October 29, 2024
, and
October 29, 2024
(File No. 001-38105); and
(d)
The description of the Company's common stock contained in our Annual Report on
Form
    10-K
for the year ended December 31, 2022, filed with the SEC on March 31, 2023, as
Exhibit 4.6
(File No. 001-38105),
    including any amendment or report filed for the purpose of updating such description.
Additionally, all documents
filed by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the initial registration statement
of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) the date of this prospectus and
before the termination or completion of any offering hereunder, shall be deemed to be incorporated by reference into this prospectus from
the respective dates of filing of such documents, except that we do not incorporate any document or portion of a document that is "
furnished
"
to the SEC, but not deemed "
filed.
"
We will provide, without charge,
to each person to whom a copy of this prospectus is delivered, including any beneficial owner, upon the written or oral request of such
person, a copy of any or all of the documents incorporated by reference herein, including exhibits. Requests should be directed to: Attention:
Corporate Secretary, 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, telephone (650) 507-0669 . The documents
incorporated by reference may be accessed on the "
Investors
"—"
SEC Filings
"—"
All
SEC Filings
" page of our website at www.180lifesciences.com. We do not incorporate the information on our website into this
prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website
as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate
by reference into this prospectus or any supplement to this prospectus).
Any statement contained in
a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for
purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.
11
Cautionary Note
Regarding Forward-Looking Statements
This prospectus contains forward-looking
statements under federal securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by the following words: "
anticipate,
" "
believe,
"
"
continue,
" "
could,
" "
estimate,
" "
expect,
" "
intend,
"
"
may,
" "
ongoing,
" "
plan,
" "
potential,
" "
predict,
"
"
project,
" "
should,
" or the negative of these terms or other comparable terminology, although not
all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and
will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking
statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and
other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by the forward-looking statements in this prospectus, including those incorporated by reference into the section
entitled "
Risk Factors
" herein.
In particular, forward-looking
statements include, but are not limited to, any statements that are not statements of current or historical facts, such as statements
relating to our expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of
our product candidates, the accuracy of our estimates regarding expenses, future revenues and capital requirements, our ability to execute
our plans to develop and market new drug products and the timing and costs of these development programs, and estimates of the sufficiency
of our existing capital resources combined with future anticipated cash flows to finance our operating requirements.
Such statements are based
on management's current expectations and include, but are not limited to:
●
The need for additional funding, our ability to raise funding
in the future, the terms of such funding, and dilution caused thereby;
●
our ability to create or purchase a front end for our back
end blockchain casino intellectual property assets, commercialize our planned blockchain casino, obtain required licenses and customers,
and come to mutually agreeable contractual terms with third parties and suppliers, and ultimately generate revenues through such operations;
●
expectations for the clinical and preclinical development,
manufacturing, regulatory approval, and commercialization of our product candidates;
●
the uncertainties associated with the clinical development
and regulatory approval of the Company's drug candidates, including potential delays in the enrollment and completion of clinical
trials, issues raised by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the U.K. Medicines and
Healthcare products Regulatory Agency (MHRA);
●
regulatory developments in the United States and foreign
countries;
●
our success in retaining or recruiting, or changes required
in, our officers, key employees or directors;
●
current negative operating cash flows and our potential ability
to obtain additional financing to advance our business and the terms of any further financing, which may be highly dilutive and may include
onerous terms;
●
the continued impact of the COVID-19 pandemic on our business
operations and our research and development initiatives;
●
the accuracy of our estimates regarding expenses, future
revenues and capital requirements;
●
the Company's reliance on third parties to conduct
its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies, the ability to come to mutually agreeable
terms with such third parties and partners, and the terms of such agreements;
●
the terms of the Company's current licensing agreements,
and the termination rights associated therewith;
●
estimates of patient populations for the Company's
planned products;
●
unexpected adverse side effects or inadequate therapeutic
efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability
claims;
12
●
the Company's ability to fully comply with numerous
federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to
its product development activities;
●
challenges and uncertainties inherent in product research
and development, including the uncertainty of clinical success and of obtaining regulatory approvals; and uncertainty of commercial success;
●
the ability of the Company to execute its plans to develop
and market new drug products and the timing and costs of these development programs;
●
changing rates of inflation and interest rates, and economic
downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war
(including the ongoing Ukraine/Russian conflict, and Israel/Hamas conflict) and other large-scale crises;
●
estimates of the sufficiency of our existing capital resources
combined with future anticipated cash flows to finance our operating requirements;
●
the review and evaluation of strategic transactions and their
impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential
future strategic transactions and the terms thereof;
●
our ability to maintain our listing of our common stock and
public warrants on the Nasdaq Capital Market, including our current non-compliance with Nasdaq's continued listing rules due to
our failure to maintain a majority of independent directors and an audit committee of at least three independent directors;
●
the reliance on suppliers of third-party gaming content and
the cost of such content;
●
the ability of the Company to obtain gaming licenses;
●
the Company's reliance on its management;
●
the potential effect of economic downturns, recessions, changes
in interest rates and inflation, and market conditions, including recessions, decreases in discretionary spending and therefore demand
for our products, and increases in the cost of capital, related thereto, among other affects thereof, on the Company's operations
and prospects as a result of increased inflation, increasing interest rates, global conflicts and other events;
●
the Company's ability to protect its proprietary information
and intellectual property (IP);
●
the ability of the Company to compete in the iGaming market;
●
the effect of current and future regulation, the Company's
ability to comply with regulations (both current and future) and potential penalties in the event it fails to comply with such regulations
and changes in the enforcement and interpretation of existing laws and regulations and the adoption of new laws and regulations that
may unfavorably impact our business;
●
the ability to compete against existing and new competitors;
●
the ability to manage expenses associated with sales and
marketing and necessary general and administrative and technology investments;
●
general consumer sentiment and economic conditions that may
affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic
slowdowns; and
●
other risks and uncertainties, including those described
under "
Risk Factors
", herein.
Any forward-looking statements
in this prospectus reflect our current views with respect to future events or to our future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. All forward-looking statements included herein speak only as
of the date of this prospectus. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our
behalf, are expressly qualified in their entirety by the cautionary statements above. Except as required by law, we assume no obligation
to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
13
Use of Proceeds
We will not receive any of
the proceeds from the sale by the Selling Stockholder of the Shares in this offering. However, if all of the Warrants that are covered
by this prospectus are exercised for cash, we may receive proceeds of up to approximately $2,850,207. We cannot predict when, or if, the
Warrants will be exercised. It is possible that the Warrants may expire and may never be exercised for cash. We intend to use any proceeds
from the exercise of the Warrants for operationalizing and developing our recently acquired Technology Gaming Platform, and general corporate
and legal expenses. Our management will have broad discretion over the use of proceeds from the exercise of the Warrants.
The Selling Stockholder will
pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholder for brokerage, accounting, tax or legal
services or any other expenses incurred by the Selling Stockholder in disposing of the Shares. We will bear all other costs, fees and
expenses incurred in effecting the registration of the Shares covered by this prospectus, including all registration and filing fees,
and fees and expenses of our counsel and our independent registered public accountants.
14
Dividend Policy
We have never paid or declared
any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. We anticipate that we will
retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay
dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common
stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.
15
Beneficial Ownership
of Securities
Security Ownership of Management and Certain
Beneficial Owners and Management
The following table contains
information regarding the beneficial ownership of our voting stock as of November 15, 2024 (the "
Date of Determination
"),
held by (i) each stockholder known by us to beneficially own more than 5% of the outstanding shares of any class of voting stock;
(ii) our directors; (iii) our Named Executive Officers as defined in the Summary Executive Compensation Table of our Annual
Report on Form 10-K for the year ended December 31, 2023, which is incorporated by reference herein; and (iv) all current directors
and executive officers as a group. Except where noted, all holders listed below have sole voting power and investment power over the shares
beneficially owned by them. Unless otherwise noted, the address of each person listed below is c/o 180 Life Sciences Corp., 3000 El Camino
Real, Bldg. 4, Suite 200, Palo Alto, California 94306.
Beneficial ownership has been
determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned
by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares
are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an option
or warrant or upon conversion of a convertible security) within 60 days of the date as of which the information is provided. In computing
the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person
by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table
does not necessarily reflect the person's actual voting power at any particular date.
Beneficial ownership as set
forth below is based on our review of our record stockholders list and public ownership reports filed by certain of our stockholders,
and may not include certain securities held in brokerage accounts or beneficially owned by the stockholders described below.
Name and Address of Beneficial Owners
Number of
Common
Stock Shares
Beneficially
Owned
Percent of
Common
Stock**
Directors, Executive Officers and Named Executive Officers
Blair Jordan
-
-
Omar Jimenez
-
-
Ryan Smith
-
-
Jay Goodman
-
-
Lawrence Steinman
3,389
(1)
*
James N. Woody
£
-
*
Jonathan Rothbard
£
1,475
*
Quan Anh Vu
£
-
-
Ozan Pamir
£
1,736
(2)
*
All officers and directors as a group (5 persons)
3,389
*
5% Stockholders
None.
*
Less than one percent.
**
Percentages based upon 1,976,999 shares of our common stock
issued and outstanding at November 15, 2024.
£
Former Named Executive Officer, no longer serving as an officer
or director of the Company. Beneficial ownership is based on either (a) the last beneficial ownership disclosed to the Company from such
persons; or (b) the record shareholders list of the Company as of the Date of Determination, and may not reflect the total number of
shares of common stock of the Company beneficially owned by the noted individual as of such date.
(1)
Includes options to purchase 65 shares of common stock
at an exercise price of $1,501.00 per share and options to purchase 789 shares of common stock with an exercise price of $12.73 per share,
which have vested, and/or which vest within 60 days of the Date of Determination.
(2)
Includes options to purchase 473 shares of common stock
at an exercise price of $1,683.40 per share and options to purchase 789 shares of common stock with an exercise price of $12.73 per share,
which have vested, and/or which vest within 60 days of the Date of Determination, and which expire if unexercised on December 30,
2024.
Change of Control
The Company is not aware of
any arrangements which may at a subsequent date result in a change of control of the Company, except that at such time as the shareholders
of the Company have approved the issuance of shares of common stock upon conversion of our 1,000,000 shares of outstanding Series B Convertible
Preferred Stock, if ever, such shares of Series B Convertible Preferred Stock currently held by El Ray Resources, Inc., will be convertible
into 40% of outstanding shares of common stock (subject to a maximum of 10 million shares), at the time of such stockholder approval  (66.7%
of the Company's pre-issuance outstanding shares of common stock).
16
Selling Stockholder
The Shares being offered by
the Selling Stockholder consist of 1,900,138 shares of common stock issuable upon the exercise of the October 2024 Common Warrants, see
the section entitled "
Prospectus Summary—Warrants and Related Transactions
", above. We are registering
the Shares in order to permit the Selling Stockholder to offer the Shares for resale from time to time.
The table below lists the
Selling Stockholder and other information regarding the beneficial ownership of the shares of our common stock by the Selling Stockholder.
The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on its ownership of
the shares of common stock and Warrants, as of November 15, 2024, assuming exercise of the Warrants held by the Selling Stockholder on
that date, if any, without regard to any limitations on exercises. The third column lists the shares of common stock being offered by
this prospectus by the Selling Stockholder. The fourth column assumes the sale of all of the Shares offered by the Selling Stockholder
pursuant to this prospectus.
Under the terms of each of
the Warrants, the Selling Stockholder may not exercise the warrants to the extent such exercise would cause the Selling Stockholder, together
with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%, of our then
outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise
of such Warrants which have not been exercised. The number of shares of common stock in the second and fourth columns do not reflect this
limitation.
The Selling Stockholder may
sell all, some or none of their Shares in this offering. See "
Plan of Distribution
.
"
Number of Shares of Common
Stock Beneficially Owned
Prior to this Offering
(1)(2)
Number of
Shares of
Common
Stock Being
Beneficial Ownership of
Common Stock After this
Offering
(2)
Name of Selling Stockholder
Number
Percentage
Offered
Number
Percentage
Armistice Capital, LLC
(3)
1,900,138
(3)
4.99
%
(3)
1,900,138
(6)
*
*
Less than 1%.
(1)
"
Beneficial ownership
" means that a person,
directly or indirectly, has or shares voting or investment power with respect to a security or has the right to acquire such power within
60 days.
(2)
Assumes for purposes of the "
Beneficial Ownership
of Common Stock After this Offering
" that (i) all of the shares of common stock to be registered by the registration statement
of which this prospectus is a part are sold in this offering and (ii) the selling stockholder does not acquire additional shares
of our common stock after the date of this prospectus and prior to completion of this offering. The registration of this offering
of shares does not necessarily mean that the selling stockholders will sell all or any portion of the shares covered by this prospectus.
(3)
The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the
"Master Fund"), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"),
as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.  The warrants are
subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion
of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock
in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510
Madison Avenue, 7th Floor, New York, NY 10022.
(5)
Represents shares of common stock equal to 4.99% of the Company's
outstanding common stock following the issuance thereof, as a result of the beneficial ownership limitation.
(6)
The shares of common stock being offered pursuant to this
prospectus consist of 1,900,138 shares of common stock issuable upon the exercise of the October 2024 Common Warrants.
17
Plan of Distribution
The Selling Stockholder and
any of its pledgees, assignees, transferees and successors-in-interest may, from time to time, sell any or all of the Shares covered hereby
on Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These
sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:
●
ordinary brokerage transactions and transactions in which
the broker-dealer solicits purchasers;
●
block trades in which the broker-dealer will attempt to sell
the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;
●
purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;
●
an exchange distribution in accordance with the rules of the
applicable exchange;
●
privately negotiated transactions;
●
settlement of short sales;
●
in transactions through broker-dealers that agree with the
Selling Stockholder to sell a specified number of such securities at a stipulated price per security;
●
through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;
●
a combination of any such methods of sale; or
●
any other method permitted pursuant to applicable law.
The Selling Stockholder may
also sell the Shares under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.
Broker-dealers engaged by
the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA Rule 2121.
In connection with the sale
of the Shares or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The Selling Stockholder
may also sell the Shares short and deliver the Shares to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell the Shares. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other
financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial
institution of the Shares offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuant
to this prospectus (as supplemented or amended to reflect such transaction).
18
The Selling Stockholder and
any broker-dealers or agents that are involved in selling the Shares may be deemed to be "
underwriters
" within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the Shares.
We are required to pay certain
fees and expenses incurred by us incident to the registration of the Shares. We have agreed to indemnify the Selling Stockholder against
certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We agreed to keep this prospectus
effective until all of the Shares underlying the Warrants have been sold pursuant to this prospectus or Rule 144 under the Securities
Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.
Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and
regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder
or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed it of the need to deliver
a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities
Act).
19
Description of
Capital Stock
Authorized Capital Stock
The following summary of
the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities. We
urge you to read our Certificate of Incorporation, as amended in its entirety, for a complete description of the rights and preferences
of our securities.
As of the date of this prospectus,
we have 100,000,000 authorized shares of common stock, $0.0001 par value per share and 5,000,000 shares of preferred stock, $0.0001 par
value per share, of which 1,000,000 shares have been designated as Series A Convertible Preferred Stock (of which none are outstanding),
of which one share of preferred stock has been designated as a Class C Special Voting Share, of which none are outstanding, and one share
of preferred stock has been designated as a Class K Special Voting Share, of which none are outstanding, and of which 1,000,000 shares
have been designated as Series B Convertible Preferred Stock, of which 1,000,000 shares are outstanding.
As the date of this prospectus,
there were 1,976,999 shares of common stock outstanding held by 122 holders of record, and 1,000,000 shares of Series B Convertible Preferred
Stock issued or outstanding, held by one holder of record.
Common Stock
Except as otherwise required
by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of our common stock possess
all voting power for the election of our directors and all other matters requiring stockholder action and will at all times vote together
as one class on all matters submitted to a vote of our stockholders. Holders of common stock are entitled to one vote per share on matters
to be voted on by stockholders and do not have the right to cumulate votes in the election of directors.
Holders of common stock will
be entitled to receive dividends and other distributions, if any, in amounts declared from time to time by our Board of Directors in its
discretion out of funds legally available therefor and shall share equally on a per share basis in these dividends and distributions.
In the event of our
voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled
to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders, after the rights
of the holders of the preferred stock, if any, have been satisfied.
Our stockholders have no preemptive
or other subscription rights and there are no sinking fund or redemption provisions applicable to our common stock.
Our Board of Directors is
divided into two classes, with only one class of directors being elected in each year and each class generally serving a two-year term.
20
Preferred Stock
Our Certificate of Incorporation
provides that shares of preferred stock may be issued from time to time in one or more series. Our Board of Directors will be authorized
to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and
any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board of Directors will be able
to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and
other rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board of Directors to issue preferred
stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of the Company or the
removal of existing management.
Series B Convertible
Preferred Stock
The below is a summary of the rights
and preferences of the Series B Convertible Preferred Stock:
Voting Rights
. Until
such time, if ever, as the stockholders of the Company have approved the issuance of shares of common stock upon the conversion of the
Series B Convertible Preferred Stock ("
Stockholder Approval
"), the Series B Convertible Preferred Stock only has rights
to vote on amendments to the Series B Designation (which are subject to the approval of a simple majority of the holders of Series B Convertible
Preferred Stock), and the Protective Provisions, discussed below.
The Series B Preferred Stock
require the consent of the holders of at least a majority of the issued and outstanding shares of Series B Convertible Preferred Stock
to (a) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B Convertible
Preferred Stock of the Company; (b) adopt or authorize any new designation of any Preferred Stock or amend the Certificate of Incorporation
of the Company in a manner which (i) provides any holder of common stock or preferred stock any rights upon a liquidation of the
Company which are prior and superior to those of the holders of the Series B Convertible Preferred Stock; or (ii) adversely affect
the rights, preferences and privileges of the Series B Convertible Preferred Stock; (c) effect an exchange, or create a right of
exchange, cancel, or create a right to cancel, of all or any part of the shares of another class of shares into shares of Series B Convertible
Preferred Stock; (d) alter or change the rights, preferences or privileges of the shares of Series B Convertible Preferred Stock
so as to affect adversely the shares of such series; and (e) issue any shares of Series A Preferred Stock or Series B Convertible
Preferred Stock, other than the 1,000,000 shares of Series B Preferred Stock currently outstanding (collectively, the "
Protective
Provisions
").
After Stockholder Approval,
in addition to the above voting rights, each holder of outstanding shares of Series B Convertible Preferred Stock shall be entitled to
cast the number of votes in connection with the Series B Convertible Preferred Stock shares held by such holder equal to the number of
whole shares of common stock into which the shares of Series B Convertible Preferred Stock held by such holder are convertible as of the
record date for determining stockholders entitled to vote on such matter. Fractional votes shall not, however, be permitted and any fractional
voting rights available on an as-converted to common stock basis (after aggregating all fractional shares into which shares of Series
B Convertible Preferred Stock held by each holder could be converted) shall be rounded down to the nearest whole share. Except as
provided by law or by the other provisions of the Certificate of Incorporation or the Series B Designation, holders of Series B Convertible
Preferred Stock shall vote together with the holders of common stock as a single class and there shall be no series voting.
Dividend Rights
. None,
except that if the Company declares a dividend or makes a distribution of cash (or any other distribution treated as a dividend under
Section 301 of the Internal Revenue Code) on its common stock, each holder of Shares of Series B Convertible Preferred Stock is entitled
to participate in such dividend or distribution in an amount equal to the largest number of whole shares of common stock into which all
shares of Series B Convertible Preferred Stock held of record by such holder are convertible as of the record date for such dividend or
distribution or, if there is no specified record date, as of the date of such dividend or distribution. Notwithstanding the foregoing,
holders shall have no right of participation in connection with dividends or distributions made to the common stock stockholders consisting
solely of shares of common stock.
21
Liquidation Preference
.
In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each a "
Liquidation
Event
"), the holders of Series B Convertible Preferred Stock are entitled to receive prior and in preference to any distribution
of any of the assets of the Company to the holders of the common stock or securities junior to the Series B Convertible Preferred Stock
(other than the common stock) by reason of their ownership of such stock, but after any required distribution to any holders of Series
B Convertible Preferred Stock, an amount in cash per share of Series B Convertible Preferred Stock for each share of Series B Convertible
Preferred Stock held by them equal to the greater of (x) one times the Stated Value; and (y) the total amount of consideration
that would have been payable on such share upon a Liquidation Event, had such share of Series B Convertible Preferred Stock been converted
into common stock, immediately prior to such Liquidation Event (as applicable, the "
Liquidation Preference
"). The "
Stated
Value
" is $17.30 per share of Series B Convertible Preferred Stock, for a total aggregate Liquidation Preference of $17,300,000.
Conversion Rights
.
None prior to Stockholder Approval. After Stockholder Approval, at the option of the holder(s) thereof, each share of Series B Convertible
Preferred Stock is convertible into a number of shares of common stock of the Company as equals the Conversion Rate. The "
Conversion
Rate
" shall initially be 0.685 (or 685,000 shares in aggregate, which would represent 40% of the Company's then outstanding
shares of common stock (66.7% of the Company's pre-issuance outstanding shares of common stock)), as equitably adjusted, as applicable
for stock splits and recapitalizations; provided that if at any time after the original issuance date of the Series B Convertible Preferred
Stock and prior to the Stockholder Approval Date, the Company shall actually issue any additional shares of common stock of the Company
(each a "
Dilutive Issuance
"), the Conversion Rate shall be increased to a value equal to (x)(i) the total outstanding
shares of common stock ("
Total Outstanding Shares
") on the date immediately following such Dilutive Issuance,
divided by (ii) 60%, minus (iii) the Total Outstanding Shares on the date immediately following such Dilutive Issuance, divided
by (y) 1,000,000, rounded to the thousands place, as equitably adjusted, as applicable for stock splits and recapitalizations (each
a "
Dilutive Adjustment
"); provided that in no event will the Conversion Rate be greater than ten. The effect of any
change in the Conversion Rate shall not be retroactive and shall only apply for conversions of Series B Convertible Preferred Stock following
the date of any Dilutive Adjustment. The Conversion Rate is fixed at the time of Stockholder Approval and is not subject to further adjustment
thereafter. The Conversion Rate is designed to result in the holders of the Series B Convertible Preferred Stock receiving 40% of the
then outstanding shares of common stock upon conversion of the Series B Convertible Preferred Stock (66.7% of the Company's pre-issuance
outstanding shares of common stock), subject to a maximum of 10 million shares of common stock, and further subject to such conversion
ratio being fixed upon Stockholder Approval. The Conversion Rate is 1.318 or 1,318,000 total shares of common stock in aggregate as of
the date of this prospectus.
Redemption Rights
.
None.
Stock Exchange Listing
Our common stock is currently
listed on Nasdaq under the symbol "
ATNF
".
Stock Exchange Listing
The transfer agent and registrar
for our common stock is Continental Stock Transfer & Trust Company.
Certain Anti-Takeover Provisions of Delaware
Law and our Certificate of Incorporation and Bylaws
We are subject to the provisions
of Section 203 of the Delaware General Corporation Law (the "
DGCL
") regulating corporate takeovers. This statute prevents
certain Delaware corporations, under certain circumstances, from engaging in a "
business combination
" with:
●
a stockholder who owns 15% or more of our outstanding voting
stock (otherwise known as an "
interested stockholder
");
●
an affiliate of an interested stockholder; or
●
an associate of an interested stockholder, for three years
following the date that the stockholder became an interested stockholder.
A "
business combination
"
includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:
●
our Board of Directors approves the transaction that made
the stockholder an "
interested stockholder,
" prior to the date of the transaction;
●
after the completion of the transaction that resulted in the
stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction
commenced, other than statutorily excluded shares of common stock; or
●
on or subsequent to the date of the transaction, the business
combination is approved by our Board of Directors and authorized at a meeting of our stockholders, and not by written consent, by an
affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.
22
Our Certificate of Incorporation
provides that our Board of Directors be classified into two classes of directors. As a result, in most circumstances, a person can gain
control of our Board of Directors only by successfully engaging in a proxy contest at two or more annual meetings.
Our authorized but unissued
common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of
corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of
authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain
control of us by means of a proxy contest, tender offer, merger or otherwise.
Securities Eligible for Future Sale
Rule 144
Pursuant to Rule 144, a person
who has beneficially owned restricted shares of our common stock or warrants for at least six months would be entitled to sell their securities
provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months
preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the
sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period
as we were required to file reports) preceding the sale.
Persons who have beneficially
owned restricted shares of our common stock or warrants for at least six months but who are our affiliates at the time of, or at any time
during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell
within any three-month period only a number of securities that does not exceed the greater of:
●
1% of the total number of shares of common stock then outstanding;
or
●
the average weekly reported trading volume of the common stock
during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.
Sales by our affiliates under
Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about
us.
Restrictions on the
Use of Rule 144 by Shell Companies or Former Shell Companies
Rule 144 is not available
for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers
that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the
following conditions are met:
●
the issuer of the securities that was formerly a shell company
has ceased to be a shell company;
●
the issuer of the securities is subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act;
●
the issuer of the securities has filed all Exchange Act reports
and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required
to file such reports and materials), other than Form 8-K reports; and
●
at least one year has elapsed from the time that the issuer
filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.
23
Legal Matters
The validity of the securities
offered by this prospectus have been passed upon for us by The Loev Law Firm, PC. David M. Loev, the President and sole owner of The Loev
Law Firm, PC, beneficially owns less than 1% of the outstanding shares of our common stock.
Experts
The consolidated financial
statements of 180 Life Sciences Corp. and subsidiaries as of December 31, 2023 and 2022, and for each of the years in the two-year period
ended December 31, 2023, are incorporated into this prospectus by reference from 180 Life Science Corp.'s Annual Report on Form
10-K for the year ended December 31, 2023, have been audited by Marcum LLP, an independent registered public accounting firm, as set forth
in their report thereon, incorporated herein by reference, and have been incorporated in this prospectus and Registration Statement in
reliance upon such reports given on the authority of such firm as an expert in accounting and auditing.
No expert or counsel named
in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities
being registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency
basis, or had, or is to receive, any interest, directly or indirectly, in our Company or any of our parents or subsidiaries, nor was any
such person connected with us or any of our parents or subsidiaries, if any, as a promoter, managing or principal underwriter, voting
trustee, director, officer, or employee.
Where You Can Find
More Information
We file annual, quarterly
and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet
at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available, free of charge,
on our website at www.180lifesciences.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.
This prospectus is part of
a registration statement that we filed with the SEC. This prospectus omits some information contained in the registration statement in
accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information
about us and our subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an
exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by
reference to these filings. You should review the complete document to evaluate these statements.
24
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
The following table sets forth
all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the common
stock being registered. All the amounts shown are estimates except the SEC registration fee.
SEC registration fee
$
268
Legal fees and expenses
*
Accounting fees and expenses
*
Miscellaneous fees and expenses
*
Total
$
*
*
Estimated fees and expenses not presently known.
Item 14. Indemnification of Directors and Officers.
Section 145 of the DGCL authorizes
a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad
to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under
the Securities Act.
Our Certificate of Incorporation
provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our
bylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL.
In addition, we have entered
into indemnification agreements with directors, officers and some employees containing provisions that are in some respects broader than
the specific indemnification provisions contained in the DGCL. The indemnification agreements will require us, among other things, to
indemnify our directors against certain liabilities that may arise by reason of their status or service as directors and to advance their
expenses incurred as a result of any proceeding against them as to which they could be indemnified.
Item 15. Recent Sales of Unregistered Securities.
On April 5, 2023, we entered
into a placement agent agreement with A.G.P. On April 5, 2023, in connection with the placement agent agreement, we also entered into
a securities purchase agreement pursuant to which we issued and sold, in a private placement, warrants to purchase up to 82,668 shares
of our common stock at a purchase price per share of $36.29 (when including shares of common stock and pre-funded warrants to purchase
shares of common stock in a registered direct offering) in the concurrent private placement. The offering closed on April 10, 2023.
The net proceeds to us from the offering was approximately $2.7 million, after deducting placement agent fees and expenses and estimated
offering expenses payable by us. We issued the warrants to purchase up to 82,668 shares of our common stock without registration under
the Securities Act, based on the exemption from registration afforded by Section 4(a)(2) thereof and/or Rule 506(b) of Regulation
D promulgated thereunder.
On November 28, 2023, the
Company entered into Amendment No. 1 to the August SPA with a certain institutional investor (the "
Purchaser
")(the
"
December 2023 SPA Amendment
"), pursuant to which (i) the Purchaser agreed to pay an additional $830,769.30 in connection
with the repricing of the August 2023 Shares and August 2023 Pre-Funded Warrants (the "
Repricing Amount
"), (ii) the
Company agreed to issue to the Purchaser (x) pre-funded warrants to purchase up to 257,205 shares of common stock, with an exercise price
of $0.0001 per share (the "
December 2023 Pre-Funded Warrants
"), and (y) warrants to purchase up to 477,058 shares of
common stock, with an exercise price of $0.17 per share (the "
December 2023 Common Warrants
" and, together with the
December 2023 Pre-Funded Warrants, the "
December 2023 Warrants
"), and (iii) the Company and the Purchaser agreed to
enter into the Warrant Amendment Agreement.
II-
1
In accordance with the December
2023 SPA Amendment, the Company entered into a warrant amendment agreement with the Purchaser, dated November 28, 2023 (the "
December
2023 Warrant Amendment Agreement
"), whereby the Company agreed to amend the following outstanding warrants held by the Purchaser:
(i) warrants to purchase up to 135,339 shares of common stock, issued on December 22, 2022, and amended in January 2023, April 2023 and
August 2023; (ii) warrants to purchase up to 16,138 shares of common stock, issued on July 20, 2022 and amended in April 2023 and August
2023; (iii) warrants to purchase up to 82,668 shares of common stock, issued on April 10, 2023 and August 2023; and (iv) warrants
to purchase up to 242,915 shares of common stock underlying the August Common Warrants (collectively, the "
Existing Common Warrants
").
Pursuant to the Warrant Amendment Agreement, the Existing Common Warrants were amended (the "
December 2023 Warrant Amendment
")
to not be exercisable until the Company obtained stockholder approval for the issuance of up to 477,058 shares of common stock upon exercise
of the Existing Common Warrants (the "
Existing Common Warrant Shares
"), which stockholder approval was received on
February 16, 2024. Pursuant to the December 2023 Warrant Agreement, the Existing Common Warrants were amended to have an exercise price
of $3.23 per share, and to expire on the fifth anniversary of the date that the stockholders of the Company approved the issuance of shares
of common stock upon exercise of such Existing Common Warrants, which stockholder approval date, which was February 16, 2024.
The warrants and the warrant
shares have not been registered under the Securities Act, and were instead offered pursuant to the exemption provided in Section 4(a)(2)
under the Securities Act.
On February 21, 2024, February
28, 2024, March 6, 2024 and March 7, 2024, the holder of pre-funded warrants to purchase shares of common stock of the Company at an exercise
price of $0.0019 per share, exercised warrants to purchase 58,520, 64,684, 72,000 and 62,000 shares of common stock, respectively, for
$111.19, $122.90, $136.80 and $117.80 of cash, respectively, and was issued 58,520, 64,684, 72,000 and 62,000 shares of common stock upon
exercise thereof, respectively. The exercise of the warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities
Act.
On March 12, 2024, a holder
of Class K Special Voting Shares converted such shares into 14 shares of common stock of the Company in a transaction exempt from registration
pursuant to Section 3(a)(9) of the Securities Act. As a result of such conversion, there are no longer any Class K Special Voting Shares.
On September 30, 2024, we
closed the transactions contemplated by that certain September 29, 2024, Asset Purchase Agreement (the "
Purchase Agreement
") with
Elray Resources, Inc. ("
Elray
"), pursuant to which we acquired certain source code and intellectual property relating
to an online blockchain casino in consideration for 1,000,000 shares of newly designated Series B Convertible Preferred Stock (the "
Preferred
Stock
") and warrants to purchase 3,000,000 shares of common stock of the Company (the "
Warrants
"). The
offer and sale of the Preferred Stock and the Warrants were intended to be exempt from registration pursuant to Section 4(a)(2) and/or
Rule 506 of Regulation D of the Securities Act, since the foregoing offer, sales and issuances did not involve a public offering, the
recipient confirmed that it was an "
accredited investor
", and the recipient acquired the securities for investment
only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered
without any general solicitation by us or our representatives. The securities are subject to transfer restrictions, and the certificates
evidencing the securities will contain an appropriate legend stating that such securities have not been registered under the Securities
Act and may not be offered or sold absent registration or pursuant to an exemption therefrom.
On
October 17, 2024, the Company issued the Holder the October 2024 Warrants to purchase up to 1,900,138 shares of common stock with an
exercise price of $1.50 per share pursuant to the terms of an Inducement Agreement dated October 16, 2024. The October 2024 Warrants
were immediately exercisable and have a term of exercise of five years. The Company claims an exemption from registration pursuant to
Section 4(a)(2) and/or Rule 506 of the Securities Act for the issuance of the October 2024 Warrants since the foregoing issuance did
not involve a public offering, the recipient took the securities for investment and not resale, we took appropriate measures to restrict
transfer, and the recipient was an accredited investor. The securities are subject to transfer restrictions, and the securities contain
an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent
registration or pursuant to an exemption therefrom.
II-
2
Item 16. Exhibits.
No.
Description
1.1
Placement Agent Agreement, dated April 5, 2023, between 180 Life Sciences Corp. and A.G.P./Alliance Global Partners (filed as Exhibit 1.1 to the registrant's Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein)
1.2
Placement Agency Agreement, dated August 9, 2023, by and between 180 Life Sciences Corp. and A.G.P./Alliance Global Partners. (filed as Exhibit 1.1 to the registrant's Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)
2.1£
Asset Purchase Agreement dated September 29, 2024, by and among Elray Resources, Inc., as seller and 180 Life Sciences Corp., as purchaser (filed as Exhibit 2.1 to the registrant's Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)
3.1
Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on November 12, 2020 and incorporated by reference herein).
3.2
Certificate of Amendment of Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of Delaware on December 15, 2022 (filed as Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on December 16, 2022 and incorporated by reference herein)
3.3
Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of 180 Life Sciences Corp., filed with the Secretary of State of Delaware on February 26, 2024 (Filed as Exhibit 3.1 To the Current Report on Form 8-K filed by the registrant on February 28, 2024, and incorporated by reference herein)
3.4
Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)
3.5
Second Amended and Restated Bylaws of 180 Life Sciences Corp., effective as of September 4, 2023 (filed as10.39# Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on September 7, 2023 and incorporated by reference herein)
4.1
Specimen Common Stock Certificate (filed as Exhibit 4.2 to the registrant's Registration Statement Form S-1 filed on April 26, 2017 and incorporated herein by reference)
4.2
Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (filed as Exhibit 4.6 to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 31, 2023 and incorporated herein by reference)
4.3
Form of July Common Warrant (filed as Exhibit 4.2 to the registrant's Current Report on Form 8-K filed on July 19, 2022 and incorporated by reference herein).
4.4
Form of December Common Warrant (filed as Exhibit 4.2 to the registrant's Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).
4.5
Amendment No. 1 to the December 2022 Common Warrants, dated January 12, 2023, by and between 180 Life Sciences Corp. and the Selling Stockholder (filed as Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on January 12, 2023 and incorporated by reference herein).
4.6
Amendment No. 1 to the Warrants, dated April 5, 2023, by and between 180 Life Sciences Corp. and the Selling Stockholder. (filed as Exhibit 10.11 to the registrant's Quarterly Report on Form 10-Q filed on May 15, 2023 and incorporated by reference herein)
4.7
Form of April Common Warrant (filed as Exhibit 4.2 to the registrant's Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein)
4.8
Warrant Agent Agreement for Pre-Funded Warrants and Common Warrants, dated August 14, 2023, by and between 180 Life Sciences Corp. and Continental Stock Transfer & Trust Company. (filed as Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)
4.9
Warrant Amendment Agreement, dated August 9, 2023, by and between the Company and Armistice Capital Master Fund Ltd. (filed as Exhibit 4.4 to the registrant's Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein)
4.10
Form of Warrant Agent Agreement for December 2023 Pre-Funded Warrants and Common Warrants (filed as Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)
II-
3
4.11
Form of December 2023 Pre-Funded Warrant (included as Annex A to Exhibit 4.11) (filed as Exhibit 4.2 to the registrant's Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)
4.12
Form of December 2023 Common Warrant (included as Annex B to Exhibit 4.11) (filed as Exhibit 4.3 to the registrant's Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)
4.13
Warrant Amendment Agreement, dated November 28, 2023, by and between the Company and the Purchaser (filed as Exhibit 4.4 to the registrant's Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein)
4.14
Common Stock Purchase Warrant to purchase 3,000,000 shares of common stock dated September 30, 2024, granted by 180 Life Sciences Corp. to Elray Resources, Inc. (filed as Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on October 3, 2024 and incorporated by reference herein)
4.15
Form of Warrant to Purchase 1,900,138 Shares of Common Stock Dated October 17, 2024 (filed as Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)
5.1*
Opinion of The Loev Law Firm, PC.
10.1
Registration Rights Agreement among the registrant and certain securityholders (filed as Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on June 7, 2017 and incorporated by reference herein)
10.2
Form of Indemnity Agreement (filed as Exhibit 10.8 to the registrant's Registration Statement Form S-1 filed on April 26, 2017 and incorporated by reference herein)
10.3
Form of Guarantee and Commitment Agreement (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on July 26, 2019 and incorporated herein by reference)
10.4#
180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on November 12, 2020 and incorporated by reference herein)
10.5#
Form of Stock Option Agreement (Independent Directors August 2021 Grants) (filed as Exhibit 10.9 to the registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021 filed on August 16, 2021 and incorporated herein by reference)
10.6#
Form of Stock Option Agreement 180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 4.2 to the registrant's Form S-8 filed on September 30, 2021 and incorporated by reference herein)
10.7#
Form of Restricted Stock Grant Agreement and Stock Option Agreement 180 Life Sciences Corp. 2020 Omnibus Incentive Plan (filed as Exhibit 4.3 to the registrant's Form S-8 filed on September 30, 2021 and incorporated by reference herein)
10.8
Promissory Note, dated March 15, 2019 issued to KBL IV Sponsor LLC (filed as Exhibit 10.13 to the registrant's Registration Statement Form S-4 filed on November 12, 2019 and incorporated by reference herein)
10.9
Registration Rights Agreement, dated June 12, 2020, by and among the Company and the parties signatory thereto (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on July 2, 2020 and incorporated herein by reference)
10.10
Registration Rights Agreement, dated September 8, 2020, by and among the Company and the parties signatory thereto (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on September 14, 2020 and incorporated herein by reference)
10.11
Amended and Restated Promissory Note, dated September 8, 2020, issued to KBL IV Sponsor LLC (filed as Exhibit 10.24 to the registrant's Registration Statement on Form S-1 filed on October 19, 2020 and incorporated by reference herein)
10.12
Amendment Agreement dated November 25, 2020 (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on November 27, 2020 and incorporated herein by reference)
10.13
Registration Rights Agreement dated as of February 23, 2021 by and between 180 Life Sciences Corp. and the purchasers signatory thereto (filed as Exhibit 10.4 to the registrant's Current Report on Form 8-K filed on February 24, 2021 and incorporated herein by reference)
10.14#
Consultancy Agreement dated February 22, 2021, by and between 180 Life Sciences Corp. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on March 3, 2021 and incorporated herein by reference)
II-
4
10.15#
Ozan Pamir — Stock Option Agreement effective February 26, 2021 (filed as Exhibit 10.5 to the registrant's Current Report on Form 8-K filed on March 3, 2021 and incorporated herein by reference)
10.16#
First Amendment to Consultancy Agreement dated March 31, 2021, by and between 180 Life Sciences Corp. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on April 2, 2021 and incorporated herein by reference).
10.17
Registration Rights Agreement dated as of August 23, 2021 by and between 180 Life Sciences Corp. and the purchasers signatory thereto (filed as Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on August 24, 2021 and incorporated herein by reference).
10.18#
Consulting Agreement dated November 17, 2021, by and between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on November 18, 2021 and incorporated by reference herein).
10.19#
First Amendment to Consulting Agreement dated April 27, 2022, between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.5 to the registrant's Current Report on Form 8-K filed on April 28, 2022 and incorporated by reference herein).
10.20#
Second Amendment to Consulting Agreement dated April 27, 2022, between Cannbiorex Pharma Ltd. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.6 to the registrant's Current Report on Form 8-K filed on April 28, 2022 and incorporated by reference herein).
10.21#
Second Amendment to Consulting Agreement dated May 26, 2022 and effective as of June 1, 2022, between 180 Life Sciences Corp. and Lawrence Steinman, M.D (filed as Exhibit 10.4 to the registrant's Current Report on Form 8-K filed on May 26, 2022 and incorporated by reference herein).
10.22#
180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on June 14, 2022 and incorporated by reference herein).
10.23£
Securities Purchase Agreement dated July 17, 2022, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on July 19, 2022 and incorporated by reference herein).
10.24
Warrant Agent Agreement for the July 2022 Common Warrants, dated July 29, 2022, by and between 180 Life Sciences Corp. and Continental Stock Transfer & Trust Company (filed as Exhibit 10.43 to the registrant's Registration Statement on Form S-1 filed on May 5, 2023 and incorporated by reference herein).
10.25£
Securities Purchase Agreement dated December 20, 2022, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).
10.26
Warrant Agent Agreement for the December 2022 Common Warrants, dated December 22, 2022, by and between 180 Life Sciences Corp. and Continental Stock Transfer & Trust Company (filed as Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on December 22, 2022 and incorporated by reference herein).
10.27#
Third Amendment to Consulting Agreement dated December 28, 2022, between 180 Life Sciences Corp., Cannbiorex Pharma Ltd. and Prof. Jagdeep Nanchahal (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on December 29, 2022 and incorporated by reference herein).
10.28#
Amendment to the Warrant Agent Agreement, dated January 13, 2023, by and between 180 Life Sciences Corp. and Continental Stock Transfer & Trust Company (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on January 18, 2023 and incorporated by reference herein).
10.29£
Securities Purchase Agreement dated April 10, 2023, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on April 10, 2023 and incorporated by reference herein).
10.30#
First Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on July 10, 2023 and incorporated by reference herein).
10.31£
Securities Purchase Agreement dated August 9, 2023, by and between 180 Life Sciences Corp. and the Institutional Investor. (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on August 15, 2023 and incorporated by reference herein).
II-
5
10.32#
Form of Stock Option Agreement (First Amended and Restated 2022 Omnibus Incentive Plan) (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on September 7, 2023 and incorporated by reference herein).
10.33£
Amendment No. 1 to the Securities Purchase Agreement, dated November 28, 2023, by and between 180 Life Sciences Corp. and the Purchaser (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on November 29, 2023 and incorporated by reference herein).
10.34#
Third Amendment to Consulting Agreement dated January 10, 2024 and effective as of January 1, 2024, between 180 Life Sciences Corp. and Lawrence Steinman, M.D. (filed as Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on January 17, 2024 and incorporated by reference herein).
10.35#
Offer Letter between 180 Life Science Corp. and Blair Jordan (director) dated February 24, 2024 and effective February 28, 2024 (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on February 29, 2024 and incorporated by reference herein).
10.36#
Offer Letter between 180 Life Science Corp. and Omar Jimenez (director) dated March 4, 2024 and effective March 7, 2024 (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on March 11, 2024 and incorporated by reference herein).
10.37#
Offer Letter between 180 Life Science Corp. and Ryan L. Smith (director) dated March 5, 2024 and effective March 7, 2024 (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on March 11, 2024 and incorporated by reference herein).
10.38#
Second Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed on February 16, 2024, and incorporated herein by reference)
10.39#
Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Jonathan Rothbard (filed as Exhibit 10.3 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)
10.40#
Fourth Amendment to Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Lawrence Steinman (filed as Exhibit 10.4 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)
10.41#
Executive Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp., Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc. (filed as Exhibit 10.5 to the Current Report on Form 8-K filed on May 9, 2024, and incorporated herein by reference)
10.42
Separation and Release Agreement dated September 5, 2024 and First Amendment to Separation and Release Agreement dated September 5, 2024, by and between Cannbiorex Pharma Ltd., 180 Life Sciences Corp. and Sir Marc Feldmann (filed as Exhibit 10.1 to the Current Report on Form 8-K filed on September 9, 2024, and incorporated herein by reference)
10.43
Indemnity Agreement dated September 3, 2024 and effective September 5, 2024, between 180 Life Sciences Corp. and Sir Marc Feldmann (filed as Exhibit 10.2 to the Current Report on Form 8-K filed on September 9, 2024, and incorporated herein by reference)
10.44
Form of Warrant Inducement Agreement, by and between the Company and Holder dated October 16, 2024 (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)
10.45
Financial Advisory Agreement, dated as of October 16, 2024, between A.G.P./Alliance Global Partners and the Company (filed as Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on October 16, 2024 and incorporated by reference herein)
10.46+
Offer Letter between 180 Life Science Corp. and Jay Goodman (director) dated October 25, 2024 and effective October 24, 2024 (filed as Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the Commission on October 29, 2024 and incorporated herein by reference).
21.1
List of Subsidiaries (filed as Exhibit 21.1 to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 31, 2023 and incorporated herein by reference).
23.1*
Consent of Marcum LLP, independent registered public accounting firm.
23.2*
Consent of The Loev Law Firm, PC (included in Exhibit 5.1).
24.1*
Power of Attorney (included on signature page of this Registration Statement).
107*
Filing Fee Table.
*
Filed herewith.
#
Management contract or compensatory plans or arrangements.
£
Certain schedules and exhibits have been omitted pursuant
to Item 601(a)(5) of Regulation S-K.
II-
6
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus
required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "
Calculation
of Registration Fee
" table in the effective registration statement;
(iii) To include any
material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;
provided
,
however
, that paragraphs
(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section
15(d) of the Securities Exchange Act that are incorporated by reference in the registration statement, or is contained in a form
of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2) That, for the purpose
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose
of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance
on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.
Provided
,
however
,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use.
(5) The undersigned registrant
hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(6) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.
II-
7
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Palo Alto, State of California, on November 15, 2024.
180 LIFE SCIENCES CORP.
By:
/s/ Blair Jordan
Name:
Blair Jordan
Title:
Interim Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE
PRESENTS, that the persons whose signature appears below constitute and appoint Blair Jordan and Omar Jimenez, and each of them, as true
and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any
registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933),
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such
things in their names and behalf in their capacities as officers and directors to enable 180 Life Sciences Corp. to comply with the provisions
of the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully
to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated.
Signature
Title
Date
/s/ Blair Jordan
Interim Chief Executive Officer and Director
November 15, 2024
Blair Jordan
(Principal Executive Officer)
/s/ Omar Jimenez
Chief Financial Officer and Director
November 15, 2024
Omar Jimenez
(Principal Financial and Accounting Officer)
/s/ Lawrence Steinman
Director
November 15, 2024
Lawrence Steinman
/s/ Ryan Smith
Director
November 15, 2024
Ryan Smith
/s/ Jay Goodman
Director
November  15, 2024
Jay Goodman
II-
8